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ABSTRACT 
 
Rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA) 
and axial spondyloarthritis (AxSpA; including ankylosing spondylitis) are 
inflammatory rheumatic diseases contributing to a substantial burden on both the 
patient and society. During the past couple of decades, active treatment strategies and 
pharmacological advancements have altered their cost structures, with scarce data 
existing on modern cohorts. Particularly for JIA in adulthood, the cost outcomes and 
clinical outcomes remain poorly documented. For these four rheumatic diseases, we 
set out to explore the health service-related costs, with emphasis on both costs of the 
index rheumatic disease and the costs of comorbidities. We investigated unmet needs 
by identifying disease-related factors attributable to distinct healthcare utilization 
patterns. 
 
We linked two population-based databases: a longitudinal clinical dataset with high 
diagnostic validity from the Jyväskylä Central Hospital rheumatology unit, and 
administrative data covering all public healthcare in the area. Collection of the clinical 
data took place between May 2007 and March 2016, and health service-related costs 
in euros (€) were available for fiscal year 2014. We studied the clinical outcomes in 218 
adult JIA patients, with health service-related costs available for 119 adult patients with 
JIA, 213 with PsA, 1086 with RA, and 277 with AxSpA. We compared their cost 
distributions and high healthcare utilization patterns. 
 
Despite being heterogeneous, particularly regarding age, JIA, RA, PsA, and AxSpA 
shared similar patterns of healthcare resource utilization, both in terms of costs 
incurred by the rheumatic disease and by comorbidities. The majority of patients are 
doing overall well both in terms of patient-reported outcomes and health service-
related costs, reflecting the effects of modern anti-rheumatic treatment. However, a 
tenth was recognizable as high healthcare utilizers (for JIA, 15%). Particularly pain, 
fatigue and disability, but also comorbidity and disease activity emerged as key factors 
affecting healthcare resource utilization. For all diseases, comorbidities accounted for 
two thirds of the total costs. 
 
This study supports the existing evidence that active treatment of rheumatic diseases 
has entailed good outcomes and low healthcare resource utilization for the majority.  
Particularly chronic pain, fatigue, and disability seem to be important areas needing 
attention in treatment of rheumatic diseases. 	  
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TIIVISTELMÄ 
 
Nivelreuma, nivelpsoriaasi, lastenreuma ja selkärankareuma lukeutuvat 
tulehduksellisiin reumasairauksiin, jotka voivat aiheuttaa merkittävää haittaa 
potilaiden terveydelle ja elämänlaadulle. Viimeisten vuosikymmenten aikana 
tapahtuneet kehitysaskeleet hoitoperiaatteissa ja lääkehoidossa ovat parantaneet 
sairausennustetta mutta samalla lisänneet lääkehoidon kustannuksia. Näiden 
potilaiden terveyspalvelujen käytön kustannuksista on kuitenkin niukasti nykyaikaista 
tutkimustietoa. 
 
Väitöskirjatutkimuksessa tarkasteltiin ja verrattiin näiden neljän tärkeän 
reumasairauden terveyspalvelujen käytön kustannuksia yhdistämällä kahdenlaisia 
rekisteritietoja: Keski-Suomen sairaanhoitopiirin potilastietojärjestelmän tietoja 
(GoTreatIT-monitorointi) reumasairauksia sairastavista potilaista vuosilta  
2007-2016 ja euromääräisiä hoitotuotantotietoja perustuen terveydenhuollon 
hoitoilmoitusjärjestelmään, eli terveydenhuollon yhteydenottoihin ja käynteihin 
vuodelta 2014. 
 
Ensimmäisessä osatyössä tarkasteltiin 218 potilasta, joilla oli lapsuusiässä alkanut 
reumasairaus, n.s. lastenreuma. Tärkein havaintomme oli, että tarkasteluaikana 16-30-
vuotiaista lastenreumaa sairastavista valtaosalla toimintakyky oli hyvä ja erittäin 
harvalla havaittiin työkyvyttömyyttä. Toisessa osatyössä tarkastelimme 119 aikuista 
lastenreumaa, 213 nivelpsoriaasia, 1086 nivelreumaa ja 277 selkärankareumaa 
sairastavaa potilasta. Heidän keskimääräiset palveluidenkäyttökustannuksensa olivat 
varsin samanlaiset ja noin yksi kymmenestä potilaasta tunnistettiin terveyspalvelujen 
suurkäyttäjäksi. Selkärankareumaa ja lastenreumaa sairastavat olivat keskimäärin 
selvästi nuorempia kuin nivelreuma- ja nivelpsoriaasipotilaat ja heidän elinaikainen 
kustannuskertymänsä voidaan siten olettaa suuremmaksi. Kaksi kolmasosaa 
terveyspalvelujen käytöstä johtui liitännäissairauksista ja etenkin suurkäyttäjillä 
liitännäissairauksista johtuva kustannustaakka oli merkittävä. Liitännäissairauksien 
lisäksi terveyspalvelujen käyttöön vaikuttivat kipu ja alentunut toimintakyky. 
Kolmannessa osatyössä havaittiin ryhmittelyanalyysin keinoin keskeisimmäksi hoidon 
kehittämistarpeeksi krooninen kipu: noin kolmasosa nivelreumapotilaista koki 
kroonista kipua ilman merkittävää tulehdusaktiivisuutta. 
 
Tutkimuksessa havaittiin, että terveyspalvelujen kustannustaakka oli tutkituissa 
reumasairauksissa varsin samankaltainen ja suurimmalla osalla potilaista 
terveyspalvelujen käyttöön liittyvät kustannukset ovat matalat. Pieni osa potilaista 
käyttää suurimman osan reumapotilaiden terveydenhuollon kokonaiskustannuksista. 
Tulehduksen rauhoittamisen lisäksi näiden potilaiden kohdalla tulee kiinnittää 
huomiota etenkin kivunhallintaan. 
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1. INTRODUCTION 
 
 
Infammatory rheumatic diseases cause a substantial burden to both the patient and to 
society.1-3 Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease, 
and it is from an economical perspective the best studied rheumatic disease. Psoriatic 
arthritis (PsA), axial spondyloarthritis (AxSpA), and juvenile idiopathic arthritis (JIA) 
are other rheumatic disease entities involving inflammation in joints and impacting 
functional ability – but still, compared to RA, their economic consequences are less 
studied. 
 
During recent decades, treatment strategies have evolved to render remission or low 
disease activity the main goal for RA, and also to an increasing extent for JIA, psoriatic 
arthritis, and potentially other inflammatory rheumatic diseases.4,5 Effective treatment 
strategies have translated into more favorable outcomes and into changes in health-
service needs and associated costs, particularly after biological disease-modifying anti-
rheumatic drugs (bDMARDs) entered the market.6-8 
 
JIA is diagnosed in childhood, and for some, the disease continues into adulthood. 
Only adult patients were studied in this thesis. If inflammation due to JIA has 
permanently affected the joints or the inflammation persists in adulthood, decades of 
living with the disease lead to high cumulative costs of healthcare resource utilization 
when compared, for instance, to rheumatoid arthritis, which has an age of onset much 
later in life. To prevent joint damage, children and adolescents with JIA are 
aggressively treated, but in the era of biologics, both cost outcomes and clinical 
outcomes in adult patients with JIA remain poorly documented. 
 
In addition to their index rheumatic disease, many patients carry other morbidities. 
Multimorbidity, with many existing definitions, refers to the disease burden of 
multiple concurrent diseases, while comorbidity generally refers a specific disease in 
addition to the index disease. This thesis does occasionally use the terms 
interchangeably. Although the burden of comorbidites in inflammatory rheumatic 
diseases is well recognized, their costs are often overlooked. 
 
With improvements in health status, there arises a need for updated research on 
current cost drivers, both in terms of disease characteristics and multimorbidities. 
This thesis falls under the category of cost-of-illness studies. More specifically, it 
assesses healthcare utilization, which refers to patient use of healthcare services, and 
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aims to improve upon prior research on the economic burden and cost drivers in adult 
patients with RA, PsA, AxSpA (including ankylosing spondylitis, AS), or JIA. 
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2. REVIEW OF THE LITERATURE 
 
 
This review begins with descriptions of each of the four disease entities, followed by 
an outline of the measures used in standard rheumatological care in Finland. 
Thereafter, we review the various aspects of healthcare utilization research in 
rheumatic diseases, and present the Finnish healthcare system. The emphasis is on 
health service-related direct costs, both for the index rheumatic disease and for 
multimorbidities. For JIA, we also explore the characteristics of the disease in 
adulthood. 
 
2.1 Rheumatoid arthritis 
 
2.1.1 Overview 
 
In Finland, the approximated incidence of RA is at 45 per 100,000.9 RA is a chronic 
inflammatory disease which generally manifests between ages 30 to 70, and has a 
female predisposition by a ratio of approximately 3 to 1.9 Typically, it symmetrically 
affects small and medium-sized joints, particularly the hands and feet. 
 
The genetic contributions of RA are complex. On the population level, the genetic 
factors account for approximately 60% of the variation in liability to disease.10 Of 
environmental risk factors, smoking appears to be the most harmful.11 Seropositivity 
currently refers to detection of (rheumatoid factor) RF or anti-citrullinated peptide 
antibodies (ACPA) from the blood, and seropositive RA is a fairly homogeneous 
disease. Current RA classification criteria from 2010 are based on collaborative work 
of American College of Rheumatology (ACR) and European League Against 
Rheumatism (EULAR). It involves an individual score, based on assessment of four 
domains: number and site of involved joints, serologic abnormality, elevated acute-
phase response, and symptom duration.12 In line with current treatment paradigms, 
the focus of this classification system is on features of early disease. 
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2.1.2 Treatment and outcomes 
 
Cogent evidence exists as to the decrease in morbidity and mortality of RA.13-18 Despite 
the improved outlook, there still remain patients with poor or sub-optimal response to 
treatment.19 Treatments aim to control the disease since no cure exists. The 
therapeutic target of RA follows the treat-to-target (T2T) strategy aiming at clinical 
remission or lowest achievable disease activity, with early, active treatment.20,21 
 
The Finnish guidelines recommend pharmacological treatment initiation with a 
combination of csDMARDs and intra-articular glucocorticoid injections to treat 
inflamed joints (Figure 1).22 Using combination therapy as the initial treatment has 
entailed excellent results, without a significant increase in adverse events.23 If this first-
line treatment fails, bDMARDs or targeted synthetic DMARDs (tsDMARDs) may 
be used, generally in combination with methotrexate (MTX).24 Sometimes, after a 
sufficient period in remission on medication, tapering the dose or expanding the dose 
interval of a bDMARD may be considered individually.24 In the combination 
treatment, tapering down one medication at a time, usually starting with 
glucocorticoids, is a common strategy. With discontinuation, disease activation and 
flares off medication are common and drug-free remission is reported in only 9 to 29%.25 
Therefore, the effective drug combination is often used as long as possible or 
necessary. 
 
For all rheumatic diseases, the long-term safety of bDMARDs is an area actively 
investigated. For instance, recent evidence has found no substantial risk increase for 
cancer in bDMARD users, compared to bDMARD naïve patients treated with 
csDMARDs.26 However, if an association is detected, it is uncertain whether it results 
from true causality or certain biases.27 For instance, patients needing bDMARDs also 
have higher disease activity, which may affect the results. 
 
 
 
Figure 1. General treatment strategy for RA in Finland. 
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As part of an early targeted intervention, patient guidance is key, as is physician 
adherence to active treatment strategies.28 In Finland, patient guidance in chronic 
rheumatic diseases relies on a multiprofessional team, which includes e.g. trained 
rheumatology nurses, physiotherapists, and occupational therapist.29 In addition to 
pharmacological treatments, the current Finnish care guidelines emphasize the effect 
of physical training in maintaining physical function.22  
 
Even in contemporary cohorts, patients with RA show worse work outcomes than 
general population comparators.30,31 Many studies show considerable decrease in 
orthopaedic surgery for RA,32,33 probably reflecting the effectivity of the modern 
DMARD treatment. One detailed analysis found that the rates of hand and foot 
surgery show a consistent decline from 1986 to 2011.34  
 
2.1.3 Comorbidity 
 
The main contributor to excess mortality in RA is increased cardiovascular disease 
(CVD) risk35, highlighting the importance of investigating RA comorbidities. 
Approximately 6% of RA patients have suffered a cardiovascular event (myocardial 
infarction or stroke).36 RA is associated also with various other comorbidities,36,37 such 
as osteoporosis,38 diabetes,39, infections,40 depression,41 and hematological 
malignancies.42-44 The goals in management of comorbidities in both RA and other 
inflammatory rheumatic diseases include prevention, early diagnosis and active 
treatment to try preventing long-term damage. 
 
Systemic inflammation, in an interplay with traditional CV risk factors may drive the 
progression of CVD.45,46 Reducing inflammation with MTX or bDMARDs may 
both improve endothelial function and reduce the risk of coronary heart disease 
(CHD) events.47,48 Therefore, controlling disease activity to lower CVD risk is a key 
goal of the current EULAR recommendations for CVD risk management.49 
 
The relations of RA and its comorbidities are complex. For instance, some 
comorbidities are features of RA itself, and some are at least partially linked to 
pharmacological treatments. Some examples fulfilling both of these criteria are the 
increased risk for severe infections40 and gastrointestinal adverse effects.37 Moreover, 
corticosteroid treatments increase the risk for both diabetes and osteoporosis. 
Smoking is a risk factor for both RA and lung cancer, which is known to be associated 
with RA.50 Multiple domains of physical function and levels of fatigue are affected by 
increasing numbers of comorbidities.51,52 Many RA patients are elderly, and aging in 
general increases the risk for multimorbidity.53 
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2.2 Juvenile idiopathic arthritis in adulthood 
 
2.2.1 Overview 
 
Rheumatic diseases in children are rare. The diagnosis “juvenile idiopathic arthritis” 
(JIA), comprises a diverse group of disease subtypes sharing chronic inflammation, 
usually chronic arthritis, as a common feature. JIA, sometimes referred to as juvenile 
rheumatoid arthritis (JRA) or juvenile chronic arthritis (JCA) is currently classified to 
categories (Table 1) according to the International League of Associations for 
Rheumatology (ILAR).54 By definition, the symptoms present before age 16 and last 
for at least six weeks.54 The diagnosis is made by detecting subtype-specific findings 
and by exclusion of other potential causes of the symptoms. In Finland, annually 
around 140 children fall ill from JIA, with a 70% female predilection.55 
 
The clinical findings vary, particularly between subtypes.56 A common extra-articular 
manifestation of JIA is uveitis57, which seems to occur most frequently in the 
oligoarticular-onset subtype.57,58 Studies suggest that uveitis prevalence and 
complications in children have decreased in the 21st century. 59,60 Another characteristic 
of JIA is active temporomandibular joint (TMJ) arthritis, seen in up to 75% of children 
with JIA and described in all subtypes. Given the potential damage to mandibular 
growth, long-term outcomes of TMJ arthritis are unfavourable.61 However, also 
arthritis of the TMJ has benefited from the active treatment strategies and 
therapeutical advances.62 
 
The etiology of JIA is unknown, but alike many other inflammatory rheumatic 
diseases, it is likely caused by an interplay of genetic and environmental factors. 
Overall, JIA subtypes are highly heterogeneous and recent biologic discoveries argue 
for an update in the classification system.63 As an example, evidence implies that 
systemic JIA is biologically distinct from the other subtypes.63,64 
 
2.2.2 Treatment and outcomes 
 
Overall, treatment aims in JIA are inactive disease and full functional capacity. 
Treatments vary based on subtypes and symptoms, but early and aggressive treatment 
to target is key.4,65 In Finland, MTX and intra-articular glucocorticoids are 
cornerstones of current pharmacological treatments in childhood. In addition, various 
other csDMARDs, such as leflunomide, sulfasalazine and oral glucocorticoids are 
used.65 bDMARDs, a few of which are indicated in JIA, are in Finland generally used 
in patients who fail to respond to first-line treatments. Multidisciplinary therapy 
including physiotherapy, adequate eye examinations, and follow-up of a child’s growth 
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and development are essential.56 In adulthood, which is the focus of this thesis, the 
treatment patterns follow those of similar adult forms, such as the treatment of RA in 
JIA polyarthritis and oligoarthritis. 
 
Despite occasionally being limited to childhood, for some, disease activity may persist 
into adulthood. The disease course is highly variable, and depends on disease 
subtype.66 Table 1 summarizes the estimates of children and adults with active disease, 
using studies with long-term follow-up (over 5 years) and any subtype-specific 
information available. The estimates showed high variability, but the lower limits in 
children generally came from the more recent cohorts. The most favorable remission 
rates are apparent in persistent oligoarticular JIA67,68 whereas extended oligoarticular, 
systemic, and polyarticular subtypes come with a worse natural disease course. 68-70 
 
Most studies have estimated that approximately a half continue in adulthood to have 
detectable inflammation.69,71 Disease characteristics at 5 years of follow-up may better 
predict outcomes than would disease characteristics at disease onset.66,69 In a 1980s 
Norwegian cohort of 176 patients, studied 30 years after disease, up to 59% of patients 
were in clinical remission off medication; those in remission on medication comprised 
7% and active disease was present in 34%.72 In another cohort, at 17 years of follow-up, 
only 40% were in remission.66 One study published in 2002 found that in patients with 
long-standing JIA, severe disability defined as health assessment questionnaire 
(HAQ) over 1.5 was present in 42.9%.58 However, even the more recent studies have 
involved patients with disease onset before the era of current treatment regimens. 
Moreover, studies of the impact of JIA on physical functioning and work ability in 
adulthood are few. 
 
2.2.3 Comorbidities 
 
Alike the aforementioned ocular involvement, many coexisting conditions are extra-
articular manifestations of JIA. In regards of other comorbidities, the data published 
so far is limited and based on small patient populations, with even smaller numbers of 
patients with comorbidities. 
 
An important distinction is the comorbidity in children and comorbidities occurring 
in adulthood, which is the focus of this thesis. Studies in children show an association 
with autoimmune diseases, such as diabetes, celiac disease, and hypothyroidism.73-75 
Most studies are underpowered to detect subtype-specific associations, but empirical 
evidence suggests that subtypes may differ in terms of the autoimmune comorbidities. 
Raab and colleagues investigated the self-reported comorbidity in young adults (mean 
age 19.7) recruited from a biologic register and found the highest comorbidity burden 
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Subtype Arthritis Additional criteria Active disease in childhood (%)* 
Active disease in adulthood 
(%) 
Systemic JIA 1+ joints Fever, rash, lymph node enlargement, hepatomegaly and/or splenomegaly, serositis 15-30 
76-79 20-5567,69,80  
Persistent 
Oligoarthritis 
1-4 joints throughout the 
disease course - 5-30
77-79,81** 25-5067,69,80 
Extended 
Oligoarthritis 
1-4 joints during the first 6 
months of the disease, 4+ 
joints after 6 months 
- 5-6077-79,81** 35-8067,69,80 
Polyarthritis (RF 
negative) 
5+ joints during the first 6 
months of the disease RF negative 5-60
77-79,81 50-7067,69,80* 
Polyarthritis (RF 
positive) 
5+ joints during the first 6 
months of the disease RF positive, 2 or more positive tests 5-65
77-79,81 >9069,80 
Psoriatic Arthritis 1+ joints 
Arhritis and psoriasis, or arthritis and at least 2 of the 
following: 1) dactylitis, 2) nail pitting or onycholysis, 
3) psoriasis in a first-degree relative 
<5-5577-79 5569 
Enthesitis-related 
arthritis 1+ joints 
Arthritis and enthesitis, or arthritis or enthesitis with 
2 or more additional criteria, e.g. HLA-B27 antigen, 
acute anterior uveitis, or sacroiliitis with 
inflammatory bowel disease 
5-6077-79,81 4569 
Undifferentiated 
arthritis 1+ joints 
Does not fulfill criteria of any other category or fulfills 
2 or more of the other categories 0-50
77-79 069 
* Long-term follow-up 
** Extended vs persistent subtype not distinguished in all studies 
Table 1. Current JIA subtypes according to ILAR Taskforce on Classification of Childhood Arthritis, along with estimates from the literature for the proportion 
of children and adults with active disease after long-term follow-up (over 5 years). See the original article on JIA subtypes for diagnostic exclusion criteria and a 
more extensive description of the additional criteria.54 
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for systemic-onset JIA. In all subtypes, uveitis was the most common comorbidity 
(17.7%), followed by allergic rhinitis (14.5%), CVD (9.9%, no CHD detected), migraine 
(8.7%), and atopic dermatitis (8.7%).82 
 
Comorbidities become more prevalent when patients with JIA grow adult and 
become elderly. The long-term risk of CVD in JIA is uncertain,83,84 but based on 
shared pathophysiology with certain adult forms of inflammatory arthritis, some 
subtypes of JIA may share their comorbidity spectrum. 
 
Like for other rheumatic diseases, the safety of bDMARDs is closely monitored. In 
patients with JIA who have used bDMARD, the risk of malignancies, particularly 
lymphoproliferative malignancies is elevated compared to the general population, but 
the absolute risk is still low 85 and channeling bias may exist. 
 
 
2.3 Psoriatic arthritis 
 
2.3.1 Overview 
 
In patients with psoriasis, PsA occurs in approximately 6-41%, but the estimates vary 
considerably, also according to psoriasis severity.86 The incidence in Finland is 
estimated at 23/100 000/year.87 Age of onset range is wide, but in men the highest 
incidence is around ages 30 to 39.88 The clinical appearance is heterogeneous and may 
affect distal joints, particularly the joints of fingers and toes but also axial or large joint 
involvement occur.89 Peripheral arthritis may be symmetrical or asymmetrical and 
overall, this polymorphic disease may present with symptoms resembling both RA and 
AS. Nail symptoms, dactylitis, and enthesopathies are common, recurrently occurring 
features of PsA.90 The diagnosis is clinical. 
 
Although the etiopathogenesis is still somewhat unknown, insights gained from 
biomedical studies suggest involvement of T-cells in particular. Particularly the early-
onset forms of PsA and psoriasis show a higher hereditary component and more 
familial aggregation,91,92 but in general, the disease is thought to result from an 
interplay of environmental factors and immune factors in patients with genetic 
susceptibility.90,93 Much of the genetic basis of psoriatic disease and PsA resides within 
the human leukocyte antigen (HLA) region,91,94 which also might contribute some of 
the epidemiological findings suggesting gender predilection.88,91 
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2.3.2 Treatment and outcomes 
 
Appropriate care involves treating all the disease manifestations: the skin and the nails, 
if involved, and the joint symptoms, including back pain, enthesitis, and dacylitis. 
Overall, the treatment is tailored to the needs of individual patients and their 
combination of symptoms. The mainstay treatments for musculoskeletal symptoms 
are non-steroidal anti-inflammatory drugs (NSAIDs) and intra-articular 
glucocorticoid injections. If chronic inflammation is detected, csDMARDs are 
introduced early. Of csDMARDs, MTX is the commonly used in Finland; it also 
alleviates skin symptoms. Some alternatives include leflunomide and apremilast. 
Sufasalazine is used for PsA with axial involvement, although its mechanism of effect 
for alleviating these symptoms is poorly documented. Sulfasalazine does not alleviate 
the skin symptoms of psoriasis. Many bDMARDs are approved for PsA, and also 
tsDMARDs are currently reimbursed for PsA. Physical therapy, occupational 
therapy, and exercise recommendations are similar to those of other inflammatory 
rheumatic diseases. 
 
The disease course is heterogeneous: most patients manifest a relatively benign 
disease with little progression, but some have progressive disease. Some studies 
suggest that the health-related quality of life and overall disease burden may be quite 
similar in patients with RA and patients with PsA, although those with PsA may show 
a slight tendency towards worse outcomes.95,96 
 
2.3.3 Comorbidity 
 
Extra-articular manifestations include ocular involvement in form of uveitis, 
particularly in the axial form of PsA. PsA comes with an increased comorbidity burden 
both years prior and after the diagnosis.97 Psoriasis alone as well as PsA in patients 
with psoriasis, particularly moderate-to-severe psoriasis, is associated with a 
comorbidity burden and higher healthcare utilization.98-100 
 
Patients with PsA are at risk for risk of diabetes, hypertension, hyperlipidemia, 
hyperuricemia, and other metabolic risk factors.39,98,101-103 Studies from specialty clinics 
have detected increased mortality dependent mainly on CVDs, but this finding is 
unsupported by population-based studies.104,105 The association with CVDs may result 
from the metabolic risk factors, such as hypertension, high triglycerides, and high body 
mass index (BMI), which are more prevalent in individuals with PsA than in the 
general population,106 and more prevalent than in patients with psoriasis alone or 
RA.107 Addictions such as alcohol abuse in patients with psoriasis are increasingly 
 20 
appreciated in the literature.108-110 For instance, compared with the general population, 
patients with psoriasis have approximately a 60% greater risk of dying due to alcohol-
related causes.109 However, similar studies on patients with PsA are almost non-
existent. 
 
 
2.4 Axial spondyloarthritis 
 
2.4.1 Overview 
 
Spondyloarthropathies (SpA) is an umbrella term covering inflammatory rheumatic 
diseases affecting the spine, ones such as reactive arthritis, and also arthritis or 
spondylitis associated with inflammatory bowel diseases. AxSpA is a form of 
spondyloarthritis in which the predominant symptom is back pain, and where 
radiographic sacroiliitis may or may not be present. If definite radiographic sacroiliitis 
is present in imaging, the disease can be classified as ankylosing spondylitis (AS). 
AxSpA comprises both the classic form of AS along with non-radiographic axial 
spondyloarthritis; these are nowadays increasingly considered as consecutive stages of 
one single disease.111,112 
 
SpA presents with a range of clinical features,111 but many studies point toward a 
common pathophysiologic foundation for this clinically interrelated disease entity.113 
Patients may also manifest arthritis in the peripheral joints, and may present with 
enthesitis, which involves inflammation at tendon-, ligament- or joint-capsule 
insertions.114 The term “spondyloarthropathy” generally refers to an inflammatory 
disorder of the back, whereas spondyloarthritis implies that inflammation is 
detectable. 
 
The global prevalence of SpA is about 1%,111 with the estimated incidence in Finland 
being 7/100,000 for AS, and 53/100,000 for SpA,87 but with much variation in the 
estimates.111,115 The typical onset is in young adulthood. Gender predilection seems to 
vary between different disease manifestations.112,115-117 Genes within and outside the 
major histocompatibility complex (MHC) region, particularly HLA-B27 confer 
susceptibility to disease, but environmental triggers are expected to play a key role in 
causing the disease.118,119 
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2.4.2 Treatment and outcomes 
 
The ASAS-EULAR management recommendations for AxSpA list five overarching 
principles for disease management: 1) AxSpA is a potentially severe disease with 
diverse manifestations, usually requiring multidisciplinary management coordinated 
by the rheumatologist, 2) the primary goal of treating the patient with axSpA is to 
maximise long-term health-related quality of life through control of symptoms and 
inflammation, prevention of progressive structural damage, 
preservation/normalisation of function and social participation, and 3) the optimal 
management requires a combination of non-pharmacological and pharmacological 
treatment modalities, and that 4) the treatment must be based on a shared decision 
between the patient and the rheumatologist, and 5) axSpA incurs high individual, 
medical and societal costs, all of which should be considered in its management by the 
treating rheumatologist.120 
 
NSAIDs are a mainstay treatment in AxSpA, being effective both in alleviating pain 
and perhaps even in slowing down radiological progression.121 In Finland, if NSAIDs 
are insufficient, treatment with csDMARDs such as sulfasalazine is attempted prior 
to bDMARDs. This is also required for reimbursability of bDMARDs, which are 
used when patients present with moderate to severe pain in combination with high 
disease activity.120,121 Exercise is important in maintaining and improving physical 
functioning, with most of the existing evidence concerning AS.122 
 
Large advances have occurred in the field of AxSpA during the 2010s in classification, 
basic science, and therapeutics.123 Disease progression is usually slow, with mild 
symptoms at onset, but progression rates show high individual variability. A better 
understanding of the full spectrum of disease has facilitated disease identification at 
earlier stages. Reports on work outcomes show large variations between countries, 
but the risk for work disability is high both at baseline and later in the disease 
course.124,125 Even within countries, considerable variation exists in work outcomes.31 
 
2.4.3 Comorbidity 
 
Features of the disease include extra-articular manifestations such as uveitis, psoriasis, 
and inflammatory bowel disease, with their prevalences at 25.8%, 9.3%, and 6.8%.126 An 
important comorbidity to consider is the CVDs. In a meta-analysis comparing 
individuals with AS to rheumatic disease-free controls, those with AS had an odds 
ratio of 1.6 for myocardial infarction and an odds ratio of 1.5 for stroke.127 A more recent 
study by Eriksson comparing the CVD risk of AS patients to that of RA patients and 
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the general population identified a somewhat similar risk increase of 30%–50% 
compared to that of the general population. Compared to patients with RA, the risk 
increase in AS was similar for stroke, but only half as high for acute coronary syndrome 
and thrombotic events.128 
  
In a study by Ara et al on AS, 50% of patients had at least one comorbidity, the most 
common being CVD with angina being present in 7%, hypercholesterolaemia in 10%, 
and hypertension in 17%.129 A recent meta-analysis reports the pooled estimate of 
moderate to severe depression to be 15%, and many studies report higher disease 
activity in patients with depression.41 Overall, comorbidity in SpA is also associated 
with worse work outcomes.124 
 
2.5 Pain-sensitivity syndromes 
 
Fibromyalgia is a disease considered part of a spectrum of disorders with similar 
biopsychosocial underpinnings and pain mechanisms, namely centralized pain due to 
a central disturbance in pain processing, as opposed to nociceptive pain (inflammation 
or mechanical damage) or neuropathic pain (damage, injury or dysfunction in 
peripheral nerves). This spectrum, called central sensitivity syndromes, a term 
proposed by Yunus130 and adopted by many others,131-133 comprises diseases such as 
chronic pelvic pain, chronic fatigue syndrome, chronic low back pain, irritable bowel 
syndrome, and temporomandibular joint disorders.131,134,135 
 
More prevalent in women and in those of low socioeconomic status, fibromyalgia has 
an estimated worldwide prevalence of 2.7%.136 Its diagnosis is arrived at by detecting 
characteristic clinical findings and symptoms,137 supported by assessment of the tender 
points. The clinical manifestations are multifaceted, with the hallmark symptom being 
centralized pain with hyperalgesia (abnormally increased sensitivity to pain) and 
allodynia (pain from a stimulus which would not usually provoke pain). Other 
common symptoms include sleep disturbances such nonrestorative sleep, weakness, 
fatigue, and mood disorders, symptoms often shared with the other central sensitivity 
syndromes.137-140 Genetic, environmental, and neuropsychiatric factors are considered 
to predispose to the disease, although the ethiopathogenesis is highly debatable.140-144 
In a recent Finnish study on the long-term outlook of fibromyalgia, most patients’ 
symptoms persisted over the 26-year follow-up, but fluctuation and even long 
symptomless periods were detected in many.145 
 
The most recent EULAR recommendations on management of fibromyalgia strongly 
support the role of exercise and patient education and these two are also 
recommended as key initial therapies. If further therapies are needed, the 
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recommendation highlights the need for tailoring the therapy according to individual 
needs. For most other treatment strategies, both pharmacological and non-
pharmacological ones, evidence is weak, and the effect is considered modest at most. 
Pharmacotherapy, for instance with low-dose amitriptyline, is recommended mainly 
for moderate to severe fibromyalgia or sleep disturbances.146 
 
In most rheumatic diseases, pain is common symptom and therefore a core domain 
measured and targeted actively.147 The pain associated with rheumatic diseases is 
multifactorial: it may result from joint-related causes such as active inflammation or 
chronic joint destruction, but pain-regulation mechanisms may also be altered.148,149 
Modeling the different pathways of pain in rheumatic diseases has underscored the 
link between cognitive, behavioral, and emotional processes such as pain 
catastrophizing and physical disability, depression, and decreased quality of life.149,150 
In addition, fatigue is a major concern,151-153 and estimates of severe fatigue range from 
41% to 57% of patients with RA, AS, PsA, scleroderma, or systemic lupus 
erythematosus.154 
 
Several studies have detected a higher prevalence of fibromyalgia in patients with RA 
compared to the prevalence in the general population. Compared to those with 
isolated RA, RA patients with fibromyalgia show worse patient-reported outcomes 
and higher levels of disease activity, particularly due to increased sensitivity to pain.155-
158 These challenges are also recognized in the EULAR recommendations for 
management of fibromyalgia, where the authors announce the need for studies on how 
fibromyalgia should be managed when it occurs as a comorbidity to inflammatory 
arthritis.146 
 
2.6 Measuring disease activity 
 
Of the multiple existing measures for RA disese activity, DAS28 is extensively 
validated and is considered to be the gold standard by which to measure disease 
activity and its changes as a response to treatment.159 DAS28 with three items (DAS28-
3) involves assessment of the tender and swollen joints based on the 28-joint count, as 
well as a measurement of inflammatory markers, either erythrocyte sedimentation rate 
(ESR, mm/h) or C-reactive protein (CRP, mg/l). If DAS28 with four items (DAS28-
4) is used, it involves the also patient’s assessment of general health. More technical 
descriptions will be presented later. DAS28 thresholds for disease activity are often 
>5.1 for high disease activity, ≥3.2 for moderate disease activity, <3.2 for low disease 
activity, and <2.6 for low/minimal disease activity or remission.159  
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2.6.1 Challenges in measuring disease activity 
 
Multiple challenges in measuring DAS28 exist.160,161 ESR and CRP are not disease-
specific, and may rise due to infection or to other chronic diseases, as well. 
Fibromyalgia and other chronic pain may impact the tender-joint count, resulting in 
disproportionately high counts compared to the swollen joint count. Therefore, 
although DAS28-3 and DAS28-4 agree quite well at a group level, in individual 
patients the difference may be substantial due to the patient’s general health 
assesment.162,163 The score is also subject to variation between observers. More 
extensive joint counts exist, but they are used more often in clinical trials than in 
regular care,160,164 whereas the reduced 28-joint counts has shown comparable potential 
in RA in terms of ability to detect change over time.165-167 The 28-joint count, however, 
excludes the metatarsophalangeal (MTP) joints, the joints in the foot between the 
metatarsal bones and the proximal bones of the toes, which are commonly affected in 
RA, as well as the ankles. 
 
2.6.2 Measuring disease activity in other inflammatory rheumatic 
diseases 
 
As earlier described, DAS28 is suitable for measuring disease activity in RA. Although 
used in clinical trials and in clinical care, the 28-joint count and DAS28 are not optimal 
for other inflammatory rheumatic diseases.164,168 These ratings may underestimate the 
disease activity due to the complexity of symptoms seen in other inflammatory 
rheumatic diseases, such the asymmetry of symptoms often seen in PsA, or spinal 
manifestations in AxSpA. DAS28 excludes the distal interphalangeal joints (DIP) of 
the fingers, which are commonly affected by PsA, but not by RA. Importantly, it 
doesn’t capture the extra-articular manifestations occurring in many rheumatic 
diseases.  
 
Due to these limitations, specific disease activity indices have been developed for both 
PsA and AS, some of which are used and applied mostly in clinical trials. Many of 
these scores involve more extensive joint counts and/or information about extra-
articular manifestations of disease. Examples of these disease-specific scores are 
Disease Activity in Psoriatic Arthritis (DAPSA), the Composite Psoriatic Disease 
Activity Index (CPDAI), and the Ankylosing Spondylitis Disease Activity Score 
(ASDAS).169-174 The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 
is a fully patient-reported measure for disease activity.175 BASDAI, similarly to other 
patient-reported measures, may lack specificity to the disease for which it was 
developed: for instance, patients with fibromyalgia may report higher BASDAI values 
than do those with SpA.176 
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The most commonly used JIA-specific disease activity score, the juvenile  arthritis  
disease  activity  score (JADAS), was developed in children and comprises four 
measures: physician global assessment of disease activity, parent/patient global 
assessment of wellbeing, active joint count, and ESR.177 Three versions exist, with 71-
joint, 27-joint, and 10-joint counts. In patients with JIA whose disease has continued 
into adulthood, treatment patterns follow those of similar adult forms, such as the 
treatment of RA in JIA polyarthritis and oligoarthritis. Therefore, JIA patients 
followed up in adult rheumatology clinics are often evaluated with DAS28. Among 
children, adolescents, and adults, DAS28 and JADAS have shown moderate to strong 
correlation.168,177,178 Defining the disease activity criteria has been challenging even in 
children,179-181 with very little data on how these apply in adults. 
 
Although DAS28 includes a larger joint count than does JADAS-10, it still may 
underestimate disease activity perhaps because JADAS incorporates joints outside 
those included in DAS28.168 The JADAS-10 is based on the count of any joint involved, 
up to a maximum of 10 joints.177 Another noteworthy limitation is that neither JADAS 
nor DAS28 involves assessment of uveitis, an important extra-articular manifestation 
on JIA. At the time of JADAS development, no standardized grading of uveitis 
activity was available, although some definitions of clinical inactive disease involve 
uveitis defined by the Standardization of Uveitis Nomenclature (SUN)181,182  However, 
the SUN Working Group has embarked on a second phase to forge a better consensus 
for terms used for uveitis.183 
 
 
2.7 Patient-reported outcome measures in rheumatic diseases 
 
Measures involving patient-perceived symptoms have reflected changes in disease 
outcomes such as disease status184-186 and disability.187-189 They have therefore become a 
prominent part of both standard rheumatological care and research; minimising these 
symptoms experienced by the patient is one of the main treatment goals. Although RA 
has received the most attention in outcomes research, similar measurements and core 
domains for patient-reported outcomes are applied in the other rheumatic 
diseases.147,186 
 
Multiple patient-reported outcome measures have been developed and validated for 
assessing disease activity in RA.190 The patient’s assessment of global health or 
wellbeing, for instance on a scale from 0 to 10, is integrated into many disease activity 
indices, including the DAS28 with four items.159,191 The visual analogue scale (VAS) for 
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pain and fatigue, and the HAQ disability index for disability are among the most 
commonly applied tools, and were studied in this thesis. 
 
Several challenges in measuring patient-reported outcomes must be considered. 
Symptoms perceived by patients are affected by multiple factors such as age, sex, 
social, and socioeconomic factors, and by cognitive impairment.192-194 Importantly, the 
results of patient self-assessment are not specific to any level of inflammation, nor do 
they necessarily correlate with the physician-detected disease activity.163,184,195 In 
addition, considerable variation may exist between the sexes and among different age 
groups.196 Diversity of languages and cultures is a challenge in translating the 
instruments,197 and this may impact comparability of mean scores between countries. 
 
2.7.1 Measuring health-related quality of life 
 
RA and other inflammatory rheumatic diseases make a substantial impact on health-
related quality of life (HRQoL).198,199 Increasingly measured in rheumatological 
research, HRQoL can be defined as the impact of health on an individual's ability to 
function and on perceived well-being in the physical, mental and social domains of 
life.200 Due to high overlap between the commonly utilized patient-reported outcomes, 
such as pain, function, and patient global assessment, some view all of these as 
HRQoL measures.147  
 
Hundreds of instruments exist to measure HRQoL, but in rheumatic diseases, 
generic instruments are most often used. These include the popular used 36-item 
Short-Form Health Survey (SF-36), the EuroQol instrument (EQ-5D) utility index, 
and the Finnish 15-dimensional quality of life questionnaire (15D).201-203 These 
instruments cover a variety of disease-related factors and aspects of mental and social 
health, such as mobility, vitality, and depressiveness. None of them has been proven to 
perform uniformly best, and the choice of instrument depends on characteristics of the 
population and the setting in which it is used (e.g. routine care or clinical trial).200 In 
addition, to measure aspects relevant to rheumatic diseases, specific tools have been 
developed, including RAQoL for RA and the PsAQoL for PsA.204,205  
 
2.7.2 Measuring functional disability 
 
Although many definitions for disability exist, one highly cited definition is the 
following by Leonardi and colleagues: “Disability is a difficulty in functioning at the 
body, person, or societal levels, in one or more life domains, as experienced by an 
individual with a health condition in interaction with contextual factors.” 206 The 
definition encompasses the functional, psychological, and social aspects of disability. 
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This section aims to provide an overview of instruments for measuring the physical 
and functional aspects of disability in rheumatic diseases. 
 
Questionnaires involving assessment of functional status provide a valuable 
prognostic measure for multiple long-term outcomes of RA, including work disability, 
joint replacement surgery, and mortality.187-189,207 The Health Assessment 
Questionnaire (HAQ), published in 1980, was developed to assess the functional 
status in adults with arthritis. It is validated by numerous studies, and translated or 
culturally adapted into more than 60 different languages and dialects, often with only 
minor changes.208,209 
 
The disability component of HAQ, the HAQ disability index or “legacy HAQ,” is the 
tool most widely used for quantifying functional disability in rheumatic diseases. 
Multiple modifications to assess disability have been developed,209 such as the 
modified HAQ (MHAQ),210 the multidimensional HAQ (MDHAQ),211 and HAQ-
II.212 Most of the modifications are shorter versions of the HAQ. Usually the recall 
period is one week. The modified instruments often serve as a substitute for the 
original HAQ disability index in both clinical care and in research and they have 
shown reliability and validity similar to that of the original HAQ disability index,209 
although in particular the MHAQ has received criticism as lacking sensitivity to 
change and as missing certain aspects of functional impairment.213,214  
 
To calculate the HAQ disability index, the patient evaluates each item in the 
questionnaire (Table 2) and selects one of four alternatives that best matches the 
patient’s own situation during the past week, in points: can perform the act without 
any difficulty (1 point), with some difficulty (2 points), with much difficulty (3 points), 
or the patient is unable to do it (4 points).  The highest points for each section 
represent the points for the section. The points are then added up, and the resulting 
raw HAQ is then divided by 8 to calculate the final HAQ disability index, which 
ranges from 0 to 3. The HAQ measurements in this thesis were made by measuring 
the level of disability without any aids or devices, which would affect the interpretation 
of the score. 
 
Cutoffs for the HAQ disability index vary, although the usual cutoffs are the following: 
0 to 1 for no to mild disability, 1 to 2 for moderate to severe disability, and 2 to 3 for 
severe to very severe disability. However, values over 2 are rare, particularly as the 
current treatment paradigms for rheumatic diseases aim for full functional capacity.  
 
These disability indices are commonly used for evaluating disability in the various 
rheumatic diseases but disease-specific instruments also exist. The most popular 
instrument for AxSpA is the Bath Ankylosing Spondylitis Functional Index (BASFI), 
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a quickly completed patient self-assessment of eight items relevant to everyday tasks 
(bending, reaching, changing position, standing, turning, and stair-climbing) and two 
items for the ability to cope with everyday life.215 Relevant pitfalls described for BASFI 
include clustering toward the low-disability end of the distribution and the fact that it 
may lack sensitivity to detect subtle changes in function in patients without severe 
disability.171,174 In patients with PsA with or without axial involvement, BASFI shows 
a high correlation with other instruments for measuring functional disability, such as 
the HAQ, therefore offering only a limited advantage over the HAQ disability index.216 
 
Functional disability is not unique to patients with rheumatic diseases: in a survey of a 
random general population sample of 1,530 individuals living in central Finland, the 
average HAQ disability index was 0.25, with 32% of the whole sample showing at least 
some disability.196 The normative values for HAQ vary by sex and age,196 and differing 
sociodemographical factors can produce response bias in the individual HAQ items, 
although the impact on composite HAQ indices is estimated to be minor.217  
 
 
  
Item  
1 Dress yourself, including shoelaces and buttons Shampoo your hair 
2 Stand up from a straight chair Get in and out of bed 
3 
Cut your own meat 
Lift a full cup or glass to your mouth 
Open a new milk or juice carton 
4 Walk outdoors on flat ground Climb up five steps 
5 Wash and dry your whole body Get on and off the toilet 
6 Reach and bring down a 2-kg object from above your head Bend down to pick up clothing from the floor 
7 
Open car doors 
Open previously opened jars 
Turn faucets on and off 
8 
Run errands and shop 
Get in and out of a car 
Do chores such as vacuuming or yard work 
 
Table 2. The health assessment questionnaire (HAQ) items for calculating the HAQ disability 
index. 	  
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2.7.3 Measuring pain and fatigue 
 
Pain and fatigue are core symptoms experienced by patients with rheumatic diseases. 
Aspects of pain are also captured by the disability and quality of life questionnaires.151 
In rheumatological care, pain and fatigue are usually measured in a similar way: the 
patient reports the symptom experienced during the past week, often measured on a 
10-cm visual analogue scale (VAS), which is then translated to a range from 0 to 100, 
in which 0 indicates no pain, and 100 the most severe pain imaginable. A clinically 
meaningful change in pain VAS is considered to be 10 mm.218  
 
Multiple ways to measure fatigue in rheumatic diseases exist, but the single-item 
measures on a VAS or on a numeric rating scale are the most commonly used. 
Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F) provides a 
global score based on 13 items regarding physical fatigue, functional fatigue, emotional 
fatigue, and social consequences of fatigue.219,220 
 
2.8 GoTreatIt monitoring 
 
2.8.1 Overview 
 
In their daily work, rheumatologists combine information from patient examination, 
imaging and lab modalities, and most importantly, information about the patient’s 
medical history, current symptoms, and self-reported function in activities of daily 
living. Patient monitoring is considered an important part of rheumatology, and this 
practice has arisen particularly from the need to measure outcomes and to be able to 
detect patterns which could potentially lead to disability and other poor disease 
consequences.161 
 
Monitoring also aids both in clinical decision-making and in monitoring the potential 
adverse effects of medications. Multiple trials and reviews have highlighted the 
importance of quantitatitative monitoring for improving disease outcomes in 
RA.161,221,222 The TICORA study (tight control for rheumatoid arthritis)221 and the 
Finnish Rheumatoid Arthritis Combination Therapy (FIN-RACo)222 are two well-
known examples of the effect of tight control on outcomes in rheumatoid arthritis. 
This principle is also followed by the EULAR recommendations for management of 
rheumatoid arthritis.223 
 
However, the quantitative monitoring of musculoskeletal conditions is more 
challenging than monitoring variables such as cholesterol levels in cardiovascular 
 30 
diseases.224 One critical obstacle to monitoring, detecting patterns over a long periods 
of time, can be overcome by user-friendly information-technology solutions that collect 
information from different sources. One of these, the software GoTreatIt, was 
developed in in Kristiansand, Norway, by DiaGraphIT and it is widely used in Nordic 
countries as part of standard rheumatology practice.29,96,225 With GoTreatIt, the main 
goal for monitoring is to improve patient care, but the collected data can also be 
utilized in research.226 
 
GoTreatIt data are collected as part of standard care and the reliability of the data 
resides on the physicians, nurses, and medical secretaries who work in the clinic. The 
same data are utilized for a nation-wide register for biological treatment in rheumatic 
diseases (ROB-FIN), which provides observational evidence on the safety, 
effectiveness, and costs of bDMARDs and other medications. In Finland, monitoring 
data are currently being assembled and assessed for a national quality register for 
rheumatic diseases. 
 
 
2.8.2 What is measured 
 
Monitoring with GoTreatIt has been applied as standard care in the JCH since 2007. 
The clinic has developed a model to provide a one-stop service to avoiding unnecessary 
visits, collect structured patient data, and to enhance the patient experience.29 When 
arriving for a scheduled outpatient visit in the rheumatology unit in the JCH, patients 
fill in questionnaires on computers specifically serving this purpose in the waiting 
room – currently patients can also complete the questions remotely using their cell 
phone or personal computers. The questionnaires include pain, fatigue, global health, 
assessment of disease activity on a VAS, the HAQ disability index, and painful joints. 
This information is then transferred electronically to the rheumatologist who can 
inspect it prior to the appointment (Figures 2 and 3, Table 3). 
 
During the appointment, the rheumatologist documents any findings (including 
swollen and tender joints) and records any medication initiations or changes. The 
laboratory values, ESR (mm/h) and CRP (mg/l), are imported from the laboratory 
system, and can be graphically displayed alongside medications and patient-reported 
outcomes. In addition, the software calculates DAS28-ESR and DAS28-CRP scores 
for current disease activity by the formulas in Table 4.227  
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Figure 2. The graphical display of GoTreatIt monitoring showing questions of the 
Health Assessment Questionnaire.
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Figure 3. The graphical display of GoTreatIt monitoring. 
 
 
      
HEALTH STATUS     
Date 21.03.2016 22.03.2016 31.03.2016 18.05.2017 29.05.2018 
Pain 61 78 88 52 89 
Fatigue 60 76 90 97 53 
Patient global 60 77 73 78 99 
Morning stiffness 0.25 0.08 0.17 0.75 1.50 
Rheumatic activity 30 32 0 49 71 
Joint pain 79 26 25  64 
Back pain   11  75 
Back pain at night   28  72 
Change of condition Worse The same    
 
Table 3. An example of the patient-reported outcomes displayed.
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DAS28-3 (ESR) 0.56 x sqrt(TJC28) + 0.28 x sqrt(SJC28) + 0.7 x ln(ESR) x 1.08 +0.16 
DAS28-4 (ESR) 0.56 x sqrt(TJC28) + 0.28 x sqrt(SJC28) + 0.7 x ln(ESR) + 0.014 x GH 
DAS28-3 (CRP) [0.56 x sqrt(TJC28) + 0.28 x sqrt(SJC28) + 0.36 x ln(CRP + 1) ] x 1.10 + 1.15 
DAS28-4 (CRP) 0.56 x sqrt(TJC28) + 0.28 x sqrt(SJC28) + 0.36 x ln(CRP + 1) + 0.014 x GH + 0.96 
 
Table 4. Formulas for calculating the disease activity index. TJC28 = tender joint count based 
on the 28-joint count. SJC28 = swollen joint count based on the 28-joint count. GH = patient’s 
assessment of general health on a scale from 0 to 10. 
 
 
2.9 Health economics – general concepts 
 
In addition to measuring the clinical outcomes of disease, another important outcome 
aspect to measure is the overall cost of the disease and the cost and consequences of 
interventions. In regard to the troubling increase in health care expeditures worldwide 
and the emerging, often costly, personalized therapies such as individualized cancer 
therapies, efficient resource allocation in health systems is crucial. This section aims to 
give an overview of economic evaluation in healthcare in general. 
 
2.9.1 Overview of study settings 
 
Cost-of-illness (COI) assessment of the economic burden of illness on society was the 
first economic evaluation technique in the health field.228 Table 5 summarizes common 
economic evaluations, many of which focus on comparison of the relative value of 
alternative courses of action, in terms of both their costs and consequences.228-231 In 
these comparative analyses, the comparator has a monetary value, whereas the 
outcome valuation varies by study type. Both the cost-effectiveness (outcome in 
natural units) and cost-utility analyses (outcome in utilities, e.g. quality-adjusted life 
years, QALYs) are common in comparison studies. However, cost-utility analyses are 
often referred to as cost-effectiveness studies, and many studies perform multiple types 
of analyses. One benefit of a cost-utility analysis is that it allows broad comparisons of 
various interventions accross the health sector. Incremental cost-effectiveness ratio 
(ICER) refers to the ratio calculated by dividing the incremental cost of the new 
intervention by the resultant incremental change in effectiveness. This ratio reveals the 
additional cost that an intervention imposes as compared to the additional benefit it 
delivers.230,231
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Table 5. Common types of economic evaluations in health economics research. QALY = quality-adjusted life years, CAD = Canadian Dollars.
Analysis Objective Outcome valuation Drawbacks Example 
Cost of illness Assessment of the economic impact of an illness or condition None 
Descriptive, impact on 
decision-making 
unclear 
Analysing the total costs, and cost changes 
over time in RA232 
Cost-minimization 
Which is the least costly among alternative 
interventions assumed to produce equivalent 
outcomes? 
Assuming equivalent 
outcome 
Only outcomes 
measured in the same 
units can be compared 
The overall costs of nonsurgical 
management of acute Achilles tendon 
rupture were significantly lower than were 
costs of surgical management233 
Cost-effectiveness Comparison of costs with outcomes in non-monetary units 
Clinically relevant 
natural units 
Inability to make 
interdisease 
comparisons 
Mean cost to achieve remission with 
adalimumab €66,057234 
Cost-utility Comparison of costs with outcomes in non-monetary units Utilities, e.g. QALYs 
Challenges regarding 
the utility measures 
In biologic-naïve AS patients, 
secukinumab dominated all comparators, 
with the highest QALYs (16.46) at the 
lowest cost (CAD 533,010)235 
Cost benefit A monetary value placed on outcomes Monetary 
Challenging to assign 
monetary value to all 
relevant outcomes 
Implementing an exercise program to 
reduce falling in RA patients would result 
in £234,583 of savings with a net benefit of 
£118,104236 
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The analyses in this thesis fall under the category of cost-of-illness studies. The study 
setting itself has been highly questioned by many health economists as to its usefulness 
in decision-making. However, it can inform decision-makers if considered from the 
proper perspective, one which asks innovative research questions, is capable of 
measuring the true cost to society, draws its data from the actual clinical management 
of illness, and assesses factors explaining cost variability.228 
 
2.9.2 Analysis attributes 
 
Direct and indirect costs are the main way of quantifying costs: direct costs refer to 
costs associated with medical care expenditures (diagnosis, treatment, medications), 
and indirect costs generally refer to the productivity losses related to the illness, such 
as sick leaves and disability pensions, commonly measured by the human capital 
approach (HCA) or the friction cost method (FCM). HCA determines the 
productivity loss by estimating the individual’s expected future earnings, whereas the 
FCM assumes that the work input may be covered by others, thereby providing lower 
productivity costs than does the HCA.237-239  Intangible costs represent a variety of 
expenses which are hard to measure, such as pain and deterioration in quality of life. 
Another cost component that is challenging to measure is informal care, which is a 
component of direct costs comprising care provided by caregivers outside of 
healthcare, such as family and friends. 
 
Two key attributes need to be selected in comparison studies: 1) the outcome or 
endpoint, and 2) the comparator, which often is either the current standard care 
approach or no intervention.230,240 The costs and disease outcomes are commonly 
collected within randomized controlled trials or from administrative databases. 
Analyses can be undertaken from a societal or a healthcare sector perspective. The 
societal perspective incorporates all costs and outcomes regardless of who incurs the 
costs and who obtains the effects, whereas the healthcare sector perspective seeks to 
maximise population health within a fixed healthcare budget, where the costs are 
borne from formal medical care.230 
 
As costs and associated endpoints often do not accrue steadily over time, several 
attributes related to time need consideration. Importantly, the time horizon needs to 
be selected, although it is not always possible to obtain data for all optimal time frames. 
Studies comparing costs or cost-effectiveness across different years should adjust costs 
for inflation. As costs and outcomes occurring in the future often have less value than 
costs and outcomes realized today, discount rates should be applied if the study spans 
multiple years. Theoretical evidence points to adopting different discount rates based 
 36 
on the analytical perspective (societal, healthcare sector) chosen.241 Moreover, the 
commonly applied discount rate of 3% per annum230 may result in systematic biases 
against interventions with high upfront costs but long-term benefits (e.g. vaccinations) 
in favour of interventions where the costs and health effects hold a more similar time 
profile (e.g. maintenance of chronic conditions).241 Sensitivity analyses building 
different scenarios are to be recommended, particularly ones acknowledging aspects 
of uncertainty.230,240,242 For instance, analyses using intermediate outcomes or applying 
a range of discount rates deserve encouragement. 230,240,242  
 
2.9.3 Factors affecting healthcare expenditures 
 
In addition to the disease- and intervention-specific factors assessed in economic 
evaluations, a broader view of the health system should be considered when 
conducting these studies or when assessing published evidence. Table 6 lists 
important factors affecting healthcare expenditures,243-250 making a somewhat artificial 
division into 1) factors arising from healthcare systems and social services, both of 
which are strongly affected by political decision-making, and to 2) other factors such 
as disease burden and sociodemographic factors. Most of these are, however, highly 
heterogeneous and in a complex fashion interlinked, and vary between high- and low-
income countries.245,251 Although age is a sociodemographic factor, because population 
ageing is an important driver of costs on every level, it is therefore highlighted 
separately.243,252 Considering this thesis, the heterogeneity of these factors affecting 
healthcare expenditures also underlie the between-country discrepancies often seen in 
cost-of-illness studies, which also hampers detailed comparisons to prior studies. 
 
 
 
Healthcare and social services Other 
Healthcare funding sources Disease burden 
Supply and demand of health services Sociodemographic factors 
Education of healthcare professionals Population ageing 
National income Culture and religion 
Social security Environment 
Disability benefits Technology adaptation 
 
Table 6. Factors affecting healthcare expenditures, many interlinked in a complex fashion.
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2.10 Diagnosis Related Group (DRG) and DRG-like patient 
classification systems 
 
With over a thousand existing diagnosis codes in, for instance, the ICD-10 
(International Classification of Diseases, 10th Revision), further classification for both 
operational and research purposes is useful. Diagosis-related group (DRG), a patient 
classification system, was initially developed in the 1970s at the Yale university, to 
identify “products” provided by the hospital to the patient.253 Especially starting from 
the 1990s, DRG-based payment systems have been experimented with and applied 
worldwide, and most European countries have developed their own systems.254 In the 
Nordic countries, the NordDRG consortium is an example of a collaborative effort to 
develop a harmonized DRG system.255  
 
DRGs have contributed to many success stories, resulting in improvements in 
efficiency and particularly in transparency.256-260 The main aim of DRG-based systems 
is to classify the care provided to patients in clinically meaningful and economically 
homogeneous groups. This helps to determine the income of hospitals and allows 
comparisons that would not otherwise be possible.258 This principle of paying for 
hospital care is often also referred to as activity-based funding, financing, or 
costing.257,261-263  The payment formula is usually based on a base rate which is weighed 
by the cost specific for each DRG. Often, the DRGs acknowledge also the various 
patient characteristics such as age and sex. 
 
However, the different DRG systems are highly heterogeneous, particularly due to 
the different classification variables and algorithms used, and different costing 
methodologies applied.254,258,262-264 Reasons for this heterogeneity include factors such 
as availability of cost data on which to base the processes, input from various medical 
specialist associations or expert consultants, and the differing aims for group 
homogeneity, all these translating into differing numbers of groups.258 In addition, 
parts of the process may be trade secrets. 
 
As a result of the activity-based funding, several by-products have emerged, such as 
intentional upcoding and increased readmission rates.258,265 In addition, a large study 
conducted within the National Health Service (NHS) in England revealed that the 
NHS is treating more complex patients than private providers are, which would 
warrant a fairer reimbursement system.266 Many of these issues can be overcome by 
episode-based bundled payments, in which the cost of care is bundled throughout an 
episode related to the illness, a common example being a surgical procedure and the 
post-operative care and rehabilitation related to it. These episode-based payment 
 38 
systems are increasingly applied to complement or to go beyond the DRGs; they 
however, share the challenges of DRGs as to the heterogeneity of grouping 
methodologies. Importantly, their impact on reducing costs and improving quality 
must be individually evaluated.267-269  In addition, systems suitable for primary care and 
rehabilitation exist but they are applied on a much smaller scale. 
 
In Finland, the current diagnosis classification system for both primary and specialty 
care is ICD-10. ICPC-2 (International Classification of Primary Care, Second 
Edition) is another diagnostic classification used in some primary care units by both 
nurses and doctors, but it is used to a lesser extent than is ICD-10, and it comprises a 
smaller number of diagnoses. All healthcare units, both inpatient and outpatient care 
units, must report their annual activities and patient diagnoses to the National 
Institute for Health and Welfare, although this is incentivized only in specialty care, 
which receives its income by activity-based funding. Currently, Finnish expertise on 
DRGs is concentrated under the Finnish Consulting Group (FCG), which manages 
the NordDRG system for specialty care and similar tools to use for outpatient care. 
The DRG-like tool applied in this thesis was developed and owned by DRG Medical 
Systems, until it was acquired by FCG in 2016, and harmonized with similar 
classification systems. 
 
 
2.11 Methodological remarks on analyzing healthcare cost data 
 
Statistical analysis of healthcare utilization data poses several challenges. The data is 
usually heavily skewed and contains an excess of zeros owing to the proportion of 
patients incurring no costs. Costs are frequently presented as both means and 
medians, which helps to interpret data skewness. The mean can also be used to 
estimate total costs to assess the total economic burden of the population. Most 
methods are sensitive to outliers, but no guidelines exist on how to define and handle 
these outliers, some of which may contain valuable information regarding the research 
question. When applying transformations for analytical purposes, results may be 
unintuitive, and retransformations can be misleading and are therefore often 
inadvisable. To benefit clinicians and various other stakeholders, interpretability is 
essential. 
 
During the past 10 years, economic evaluations in healthcare have built on more 
advanced statistical foundations, often under a Bayesian framework.270,271 However, in 
general, simplicity is the preference in method selection.272 Among studies on the costs 
of arthritis, generalized linear models (GLMs) and ordinary least squares (OLS) 
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regression are common methods to control for confounding variables.273 Patient-level 
cost data, however, rarely meet the assumptions of the OLS regression. Instead, using 
GLMs for non-normal data offers several advantages such as the ability to choose 
among different distribution families, depending on data and model properties. More 
complex methods have also been applied but are not widely recommended, as they 
require both substantial statistical expertise and further validation.272 The main 
challenge of large registries is quality, which should be a consideration of each study 
in its own right.274 Data completeness, especially, and how well it represents the 
population of interest deserve careful consideration.  
 
Although DRGs and healthcare-cost data are a valuable source on their own, the 
utility increases considerably in combination with large-scale registries involving 
diverse patient-level data. Such data commonly involve laboratory measurements and 
comprehensive clinical information, often validated by physicians or research 
personnel. Leveraging these combined data requires a wide variety of clinical, 
statistical, and computational skills,275 but it offers a number of potential benefits. Such 
benefits include assessment of healthcare delivery and outcomes, and the potential to 
improve identification of cost drivers.274 
 
 
2.12 Healthcare resource utilization in rheumatic diseases 
 
2.12.1 Understanding the therapeutic context 
 
Not many decades ago, the long-term outlook for a majority of inflammatory 
rheumatic diseases was poor. Though spontaneous remission may occur particularly 
in early undifferentiated arthritis, a diagnosis used to indicate that at least some 
disability is likely to develop. Patients were commonly hospitalized with a spectrum of 
disease complications. 
 
Finnish studies reached the conclusion decades ago that early and active treatment of 
RA is the strategy for preventing joint destruction.21,276 This early use of csDMARDS, 
particularly early introduction of MTX, along with organized evaluation of outcomes 
were key advancements in improving the long-term outlook of RA.277,278 Other 
inflammatory rheumatic diseases have achieved further gains through these strategies. 
This strategy of csDMARD use is still the mainstay treatment for many inflammatory 
rheumatic diseases, and if the response to csDRMARDs is insufficient, bDMARDs 
can be used. 
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Another wave of advancement resulted from these bDMARDs. “Beware of the 
biologicals—hospitals may die” states an article describing the history of the 
Rheumatism Foundation Hospital, Heinola, Finland (1951-2010). Progress in disease-
modifying therapies had caused this hospital to face economic struggles leading to its 
closing.279 bDMARDs have led to great progress in treatment of many rheumatic 
diseases, such as RA, PsA, AS and certain forms of JIA. 280 
 
2.12.2 Economic aspects of bDMARDs and tsDMARDs 
 
The efficacy and safety of bDMARDs has been widely assessed, and evidence also for 
tsDMARDs is steadily accumulating. Although somewhat less popular than studies 
on efficacy and safety, economic evaluations of these therapies are frequently 
performed to justify their use. Already at their inception, bDMARDs tripled the direct 
costs for RA,281 and they still constitute the largest cost component of direct costs in 
most rheumatic diseases. In general, changes in drug quantities and prescribed 
therapies, and novel drugs, are the most important determinants of pharmaceutical 
expenditures,282 and there is no reason to believe this wouldn’t be the case also for 
rheumatological care. Given the financial pressure on health systems worldwide and 
the influence that rheumatologists have on individual treatment decisions, 
understanding the economic aspects of rheumatic disease pharmacotherapy is 
important for all rheumatologists. 
 
The first bDMARDs entered the market at the end of the 1990s, and they are now the 
fastest growing sector of therapeutics.283 Biosimilars for bDMARDs were first 
introduced to the European markets a decade ago, and with accumulating evidence 
as to their efficacy and safety to be on par with their bio-originators,284-286 biosimilars 
are increasingly prescribed and new products are licenced each year. Although the 
expenses for developing a biosimilar are only a fraction of those incurred in developing 
the bio-originator, the final price tag is affected by market competition.287 A 
considerably lower price for a biosimilar is crucial to motivate its use,287 but the 
wholesale acquisition cost (WAC) in some countries has been higher than forecast at 
entrance onto the market. For instance, filgrastim-sndz, the first biosimilar approved 
in the United States, had only a 15% lower WAC than did its bio-originator.288 
However, within countries with greater market competition, for instance within the 
EU, the estimated cost reduction is 20% to 40% lower than for the original product, 
which may yield considerable net savings when costs are accumulated over multiple 
years.289,290 This in turn might ease the inequality in accessibility of biological therapy. 
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2.12.3 Cost of illness in rheumatic diseases 
 
Even before the introduction of biosimilars, cost structures have been widely altered 
due to the modern treatment approaches of early and aggressive introduction of 
csDMARDs, and use of bDMARDs if the first-line treatment fails. Earlier, 
hospitalization formed the largest cost component in RA, but the rate of 
hospitalization has decreased33,279 and current care is outpatient-centred. Direct costs 
have risen due to drug costs attributable to bDMARDs, but this is offset by a 
decreased incidence of work disability and lower inpatient costs.6,281,291-293 Still, for some 
rheumatic diseases, the opposite trend is apparent: in gout, the hospitalization rate has 
doubled.33 
 
Generally, high disease activity and poor physical functioning are the major 
determinants of cost in rheumatic diseases. This is a plausible consequence of an active 
disease requiring treatment efforts and more frequent follow-ups, and if inflammation 
persists, the resulting permanent joint damage manifests as worse physical 
functioning. Thereby, strategies that slow down or prevent joint destruction by 
minimizing disease activity are considered favorable from an economic 
perspective.294,295 These aspects are evaluated both within randomized controlled trials 
and within real-life data, made possible by the active measuring procedures applied in 
standard rheumatological care. 
 
Due to patient volume, the majority of insights on healthcare costs and cost drivers are 
gained from studies on RA, but at present, studies exist also on much less prevalent 
rheumatic diseases such as systemic lupus erythematosus296 and giant-cell arteritis.297 
Prior studies on direct costs focus particularly on annual costs of the index disease and 
cost drivers. Previous sections have highlighted the similarities among the rheumatic 
diseases in terms of therapeutic principles and the benefits of achieving low disease 
activity. They have also highlighted the ways in which rheumatic diseases share follow-
up and measurement strategies particularly as regards patient-reported outcomes.  
However, each rheumatic disease also presents unique characteristics. This thesis 
adopts both of these perspectives, the similarity perspective by combining the four 
diseases to explore shared patterns of healthcare utilization, and their uniqueness by 
assessing the long-term clinical and cost outcomes of JIA. 
 
Considering that the majority of ealier studies are disease-specific, healthcare resource 
utilization for each disease are next reviewed in a disease-specific manner. The focus is 
on summarizing the key findings because detailed monetary reviews are neither 
particularly useful for the thesis objectives, nor easily interpretable due to study 
heterogeneity.
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2.12.4 Healthcare resource utilization in RA 
 
Earlier studies demonstrate the high healthcare costs associated with RA7,298,299 The 
economic burden of RA is substantial,7,8,291,300 and increased healthcare resource 
utilization may occur even prior to the diagnosis.301 Studies indicate an association 
between increased direct costs and higher disease activity, whereas good physical 
function comes with lower direct costs.294,295,302-305 Costs are shown to vary by RA 
treatment response and its duration.302 
 
In RA, reaching lower disease activity levels has reduced both inpatient and outpatient 
healthcare costs and utilization.295,305-308 In general, data from the modern era of 
treatments reveal an increase in medication costs, and thereby in direct costs, but this 
is offset by less work disability.6,7,291,293 
 
Estimates of the proportion of comorbidity costs vary around 50% 303,309, and the 
variation likely derives from differences in study designs and in healthcare systems. 
Concurrent diseases may also increase hospitalization rates as evidence suggests for 
two important comorbidities: CVD and depression310. However, the impact of 
comorbidities on healthcare resource utilization in RA is insufficiently studied. 
 
2.12.5 Healthcare resource utilization in JIA 
 
Studies on the economic burden of JIA are heterogeneous and limited, particularly 
studies on adulthood costs. Most studies have examined mean annual direct costs in 
children.311-314 Generally, costs are skewed toward patients with active disease.315 In 
children, costs are increased because of pain, longer disease duration, uveitis, and with 
the longer delay from symptom onset to first pediatric rheumatologist visit.314 
 
A study from the current treatment era in 23 patients of various ages, 10 of which were 
adults, reports a substantial economic burden posed by JIA with up to half the average 
costs resulting from non-healthcare costs and productivity losses.316 Another study by 
Krause and colleagues showed increased inpatient utilization in children, but this 
finding did not extend into young adulthood. However, only 38 individuals were 
followed up into adulthood.317 Minden and colleagues have conducted comprehensive 
studies on the cost of illness for both early and late JIA using German patient 
cohorts.314,318 In patients followed up until early adulthood, the costs of JIA were 
reported to be considerable, and the costs differed among the various JIA subgroups. 
However, this study comprised patients referred to hospital between 1978 and 1988, 
which is prior to current treatment strategies.318   
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2.12.6 Healthcare resource utilization in PsA 
 
PsA generates a high socioeconomic burden,97,319,320 but being a somewhat rare disease, 
studies on its economic burden particularly in the modern era are limited. A recent 
large study on 35,061 PsA patients matched to controls showed that patients with PsA 
had both a considerably higher comorbidity burden and higher healthcare utilization 
than did individuals without PsA or psoriasis.321 Cost drivers identified to date include 
disability, disease activity, number of comorbidities, and severity of skin symptoms. 
98,322-325 Disability linked to many of its cost components and impacts the all-cause costs. 
322,323,325 
 
2.12.7 Healthcare resource utilization in AxSpA 
 
Most studies are conducted on AS. The largest cost component of AS is considered 
to be indirect costs, although estimates vary, with the highest ones reaching 80%.326-328 
In AS, longer disease duration, worse physical functioning, and high disease activity 
are considered important predictors of both direct costs and total costs.129,324,327,328 Little 
data exists on non-radiographic AxSpA, but considering that it produces a disease 
burden similar to that of radiographic AxSpA, the economic burden is expected also 
to be rather similar.112 
 
 
2.13 The Finnish healthcare system – a rheumatology 
perspective  
 
Finland has universal public healthcare, funded mainly by taxation. The majority of 
the medical and much of the non-medical costs are covered by the welfare system, with 
a fifth of medical costs in 2014 being co-payments for health services and medications 
by patients.329 These co-payments are protected by price ceilings, which, for example, 
regarding medications, have ranged in the 2010 decade from 572€ to 701€. Costly 
medications such as bDMARDs are therefore generally used when their indication 
exists, although the out-of-pocket costs may for some patients guide treatment 
strategies. Compared to many European countries, access to RA treatment in Finland 
is good.330 Relevantly, the resources for treating rheumatological patients are good in 
the Jyväskylä Central Hospital (JCH) area. 
 
A parallel private sector exists, covering occupational care and treating self-paying 
individuals along with patients holding private medical insurance, the majority of 
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which are accident insurance or insurance for children. Follow-up of chronic illnesses 
is rarely done in private clinics, particularly outside the capital area. 
 
The healthcare system relies on strong public primary care, which also carries out 
follow-up of many stable chronic diseases. Many rheumatic diseases are diagnosed in 
specialty care, but if remission is sustained with csDMARDs, follow-up is usually 
transferred to primary care. In cases of symptom recurrence indicating disease activity, 
patients are referred back to the rheumatology clinic. Patients receiving bDMARDs 
are followed up in specialty care. In JCH, RA patients have follow-up visits at 3, 6, 12, 
and 24 months after the initial appointment. Thereafter, they are followed up in 
primary care with visits to the rheumatology clinic at 5 and 10 years.29 
 
Each Finnish citizen has a unique personal identification number which provides the 
opportunity to link electronic medical records systems across different care providers 
and linking data from different registries.
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3. AIMS OF THE STUDY 
 
 
I. To explore health service-related costs and long-term outcomes in adult patients 
with juvenile idiopathic arthritis. 
 
II. To compare all-cause health service-related costs of four chronic rheumatic 
diseases, and to investigate their high healthcare utilization. 
 
III. To explore rheumatoid arthritis by cluster analysis to identify patient groups in 
need of targeted measures.
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4. MATERIAL AND METHODS 	
4.1 Patients (Studies I-III) 
 
The study population in this observational, registry-based study was from the 
Jyväskylä Central Hospital (JCH) area (population 252,000 in 2014) which has 
Finland’s largest non-university hospital. Healthcare utilization data in 2014 was 
available for four municipalities in this area: Jyväskylä, Hankasalmi, Muurame, and 
Uurainen, comprising a population of approximately 140,000. Their primary care is 
delivered at the local healthcare centers, with JCH providing specialist treatment. 
Figure 4 and Table 7 demonstrate the patient cohorts in Studies I to III. 
 
4.2 Clinical data (Studies I-III) 
 
The clinical variables came from the GoTreatIT® Rheuma application 
(DiaGraphIt®), a structured digital database which prospectively collects data as part 
of the medical records. The data collection started in JCH in 200729,226 and we 
considered all data until extraction on March 16, 2016. 
 
We identified all patients 18 or older with JIA (subtypes indistinguishable), RA, PsA, 
or AxSpA, diagnosed before or in 2014. Disease duration in years was counted as of 
diagnosis date. To capture the long-term level of the clinical and patient-reported 
outcome measures, we took the median of individual repeated measures. For this same 
purpose, instead of cross-sectional examination of medications, we defined medication 
use as ever- and never-users of any DMARDS, bDMARDS, MTX, or oral 
glucocorticoids (prednisolone and prednisone). tsDMARDs were not a part of 
standard care at the time of the study.  
 
In Finland, the transition age from pediatrics to adult rheumatology is generally 16. 
One JIA patient had no rheumatology visits at age 18 but had visits at ages 16 and 17. 
This individual was excluded from Study II, but not from Study I. 
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Figure 4. Patient cohorts. In Study I, for investigating clinical outcomes, we incorporated 
patients from the JCH area who were not in the healthcare utilization dataset, which was 
available for four municipalities in the central hospital area (Jyväskylä, Hankasalmi, Muurame, 
and Uurainen). Each silhouette represents approximately 10 individuals. 
 
 
 
Table 7. Number of patients in Studies I to III. 
 
 
4.2.1 Disease activity (Studies I-III) 
 
Of disease activity indices calculated by the GoTreatIt software, we used DAS28-
3(ESR). DAS28-3 and DAS28-4 agree quite well at the group level, but among 
individual patients, the difference may be substantial due to the patients’ global 
assessment.162,163 We therefore chose to use the DAS28-3, in order to have a more 
objective disease activity measure alongside the patient-reported outcomes assessed 
separately. Thresholds applied for disease activity were the following: ≥3.2 for 
moderate or high disease activity, <3.2 for low disease activity, and <2.6 for minimal 
disease activity and remission, although we mainly focused on the long-term average 
level of disease activity. Although DAS28-3 may somewhat underestimate the disease 
activity of JIA, PsA and AxSpA, it was the most convenient disease activity measure 
for comparisons across rheumatic diseases. 
 
Study Number of patients 
I Clinical outcomes of 218 JIA patients, healthcare utilization of 137 patients 
II 119 patients with JIA, 213 with PsA, 1,086 with RA, and 277 with AxSpA 
III Of the 1,086 RA patients in Study II, 939 with RA who were complete cases and had rheumatology clinic visits during 2010-2014 
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Study I investigated the clinical outcomes for JIA. Patients were classified as having 
active disease if they had at least one contact with the rheumatology unit in 2014 with 
DAS28-3 ≥3.2. Patients with current active uveitis were indistinguishable from the 
rest.  
 
4.2.2 Patient-reported outcomes (Studies I-III) 
 
To assess pain and fatigue, we used the visual analogue scale (VAS; 0-100 during the 
past week), and for disability, the HAQ index (0-3). For HAQ disability index, 0.5 was 
defined as no or low disability, and values above 0.5 as moderate to severe disability. 
 
4.2.3 Work outcomes (Study I) 
 
We categorized employment status on the most recent visit to the rheumatology clinic 
as follows: 1) disabled or pensioner (combined, since some answered “pensioner”, 
although their age indicated that they were receiving disability pensions), 2) sick leave, 
3) unemployed, and 4) working or student. All causes of sick leave and disability were 
included, also diseases unrelated to the rheumatic disease; these were never 
distinguishable in our data. 
 
4.3 Healthcare utilization data (Studies I-III) 
 
This study falls under the category of cost-of-illness studies, assessing a specific aspect 
of direct costs - patient use of healthcare services. The analyses were conducted from 
a healthcare-sector perspective.230 Every Finnish citizen has a unique personal 
identification number, which was used for combining the clinical data with healthcare 
utilization data. We accessed routinely recorded administrative data for the fiscal year 
2014 from the electronic medical records (EMR) system. This comprises all public 
healthcare contacts, including contacts in both primary and specialty care, as well as 
contacts from outpatient care, inpatient wards, the day hospital, and the emergency 
department. One contact was defined as one healthcare encounter per diagnosis, such 
as an appointment, an inpatient episode, or tasks that include logging onto the EMR. 
The data covered all public healthcare contacts with all healthcare professionals: 
physicians, nurses, and other healthcare professionals such as rehabilitation workers. 
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4.3.1 Diagnosis groups 
 
We utilized a system similar to diagnosis-related groups (DRG),258,261,264 one suitable 
for both inpatient and outpatient care, to group contacts based on recorded diagnoses, 
either ICPC-2 or ICD-10.The grouping tool classified the ICPC-2 and ICD-10 
diagnoses into 40 categories, two of which applied only in children and were not 
included here. 
 
A tool developed by the former DRG Medical Systems, which is currently owned by 
Finnish Consulting Group Ltd, determined costs for the healthcare contacts based 
on disease category, age, sex, healthcare unit, and healthcare provider. These data 
comprised health service-related direct costs in euros rounded to the nearest integer. 
The data included costs of both rheumatic disease-related visits and other conditions, 
together referred to as all-cause costs. To avoid underestimation of costs, we also 
included the costs of contacts lacking ICD-10 or ICPC-2 codes. By being trained on 
a large body of data from both the study area and other municipalities, the grouping 
tool gave these contacts lacking a diagnosis code a cost similar to that for contacts with 
similar background characteristics. The detailed groupings and algorithms 
underlying the cost estimation are based on principles similar to those reviewed in 
section 2.10. They were not developed within this thesis and are based on trade secrets, 
and thus cannot not be published in this thesis. Because we assessed costs from only a 
single year, we applied no discount rate. 
 
If multiple diagnoses were recorded for a visit, which is often the case, the cost was 
divided equally among the diseases. For nearly a decade, many Finnish municipalities, 
together covering the health services of over one million inhabitants, have used this 
tool for cost reports and process monitoring as primary goals, and for research 
purposes as a secondary goal. In the JCH area, many public healthcare professionals 
have been trained in healthcare coding. 
 
High healthcare utilizers were identified by selecting a quantile cutpoint at which 
those above it accounted for a cost identical of those below it. The rest were defined 
as low utilizers.  
 
4.4 Cost of bDMARDs (Study I) 
 
For patients with JIA, to make use of all available data on this rare disease, we assessed 
costs of bDMARDs in 2014 from the clinical data, based on total months of use. The 
monthly cost was estimated at 1,000 € per patient (average retail price in 2014). The 
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health service-related costs included by default the intravenous bDMARDs which are 
administered at the hospital rheumatology clinic. The costs of csDMARDs were not 
retrieved. 
 
4.5 Comorbidities 
 
To examine the economic burden of comorbidities, we used two sources: 1) healthcare 
utilization data and 2) comorbidities recorded in the clinical data. The first is recorded 
by all healthcare professionals across the public healthcare system, and the latter is 
recorded into the GoTreatIt application by rheumatologists and qualified medical 
secretaries in the JCH rheumatology clinic. For the healthcare utilization data, we 
report the proportion of health service-related costs incurred by each disease category. 
 
4.6 Ethics 
 
In Finland, register-based studies require no informed consent from study subjects, 
nor ethics approval from the individual institutes. The study was approved by the 
medical director of JCH. Efforts to protect the patients in the registry were 
undertaken and we used anonymized identification numbers in the analyses. No 
patients were involved in planning or setting the research questions, nor when 
interpreting the results.  
 
4.7 Statistical analysis 
 
The cost data was non-normally distributed with a positive skew. For clinical data, we 
present the group mean of individual medians with standard deviations (SD), and for 
annual health service-related costs, the groups mean, median, and inter-quartile range 
(IQR). For both the clinical and administrative data, we report the proportion of data 
missing for the variables used. Due to few missing data, we performed no imputation. 
 
For comparing two continuous variables, we used the independent t-test and in cases 
which violated the test assumptions, we applied the Wilcoxon rank sum test. With 
more than two groups, we applied the one-way ANOVA when its assumptions were 
met. Homogeneity of variance was assessed with Levene’s test. For subsequent post-
hoc testing, we used Tukey’s honestly significant difference when the assumption of 
homogeneity of variances was met. In the skewed cost data, cost distributions of more 
than two groups were compared with the Kruskal-Wallis test. We compared 
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categorical data with the Chi-Squared test and in cases with small counts, with the 
Fisher’s Exact Test. All comparisons were unpaired and due to planned comparisons, 
we did not account for multiple comparisons. All tests were two-sided. 
 
Because patients with JIA under age 30 have likely fallen ill in the era of modern 
treatment strategies, we have compared those under and over 30. Costs in JIA 
partients with active disease were compared to costs of those with DAS28-3 <3.2, 
suggesting remission or low disease activity. 
 
For assessing factors associated with annual costs, we used a generalized linear model 
(GLM) with a Gamma distribution and a log link function. We chose the Gamma 
distribution because it models non-negative data and allows for increasing variance as 
a function of the mean. 
 
For those with non-zero costs in Study I, we constructed univariate GLMs for age, 
pain, raw HAQ, and DAS28-3. All these variables were included also in the 
multivariate analysis, adjusted by sex. No collinearity was detectable. Six patients 
whose costs exceeded the geometric mean by two SD were excluded. Often, 
interpretation of the magnitude of the regression effect estimates are challenging. For 
variables with a p-value less than 0.05 in the multivariate analysis we therefore 
calculated average marginal effects.331,332 This demonstrates how the outcome - the 
annual costs - are influenced when the independent variable of interest increases by 
one unit. For testing robustness of the associations in the multivariate GLM, we also 
performed linear regression of inverse normal transformed costs, without outlier 
exclusion. A two-part model would first assess the differences between those with zero 
and those with non-zero costs, and then continue to analyse factors associated with 
costs in the latter group. Due to the low number of patients with zero costs we did not 
perform the first step. 
 
Cluster analysis is an exploratory analysis method used in many fields for grouping 
based on similarity.333-336 In agglomerative hierarchical clustering, all individuals start 
in their own group and the two groups of individuals that are the closest to each other 
according to the similarity measure are merged. The procedure thus generates one 
clustering of individuals for each possible number of clusters. The clustering variables 
selected were health service-related costs, median DAS28-3, median HAQ index, and 
median pain. We conducted an agglomerative hierarchical clustering by Ward's 
method.337 After taking the square root of costs to reduce the effect of outliers and 
scaling the clustering variables, the similarity measure was defined by the Euclidean 
distance. The number of clusters chosen for a more detailed examination was based 
on inspection of the dendrogram. We also performed the standard principal 
component analysis (PCA)338 to visualize the clusters. 
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When using boxplots for data visualization, the black line represents the median, the 
box the inter-quartile range (IQR = Q3−Q1), the lower whisker Q1–1.5*IQR, and the 
upper whisker Q3+1.5*IQR. In violin plots, the white dot represents the median. 
Sequel Pro 1.1.2 was used to manage healthcare utilization data in a MySQL database. 
All other data handling and statistical analyses were carried out with R programming 
version 3.2.4 (R Foundation for Statistical Computing, Vienna, Austria). Conversion 
to marginal effects was replicated with Stata Corp version 12.1 (Stata Corp, College 
Station, TX, USA) since it has more methods than R for obtaining marginal effects.	  
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 5. RESULTS 
5.1 Characteristics of the study population (Studies I-III) 
Study I comprised 218 adult patients with JIA. Study II comprised 119 adult patients 
with JIA, 213 with PsA, 1,086 with RA, and 277 with AxSpA (Table 8). As of 2007 
when GoTreatIt data collection began, up until data extraction in March 2016, the 
mean observation time for patients with JIA with healthcare-utilization data was 4.6 
years (median 4.8 years, IQR 2.9-6.4), for RA a mean 5.9 years (6.5, 4.9-7.1), for PsA 
5.0 years (5.4, 3.6-6.8), and for AxSpA 4.7 years (5.1, 3.0-6.5). Of these patients, only one 
visit to the clinic during the follow-up occurred for 10.1% of patients with JIA, for 10.8% 
with PsA, for 12.5% with RA, and for 18.4% with AxSpA. Of the 1,086 patients with 
RA, 1,013 with information on classification criteria all fulfilled the ACR/EULAR 
criteria. In patients with RA, RF was positive for 62.0% and ACPA for 55.6%. Of all 
patients with JIA, RF was positive for 6.7%.  
Study III comprised 939 RA patients with no missing data, who had visits to the 
rheumatology clinic between 2010 and 2014. In both global and pairwise comparisons, 
all rheumatic disease groups differed in age (p < 0.001), JIA patients being the 
youngest with mean age 32.4, and RA patients the oldest with mean age 62.6. In 
addition, sex distributions differed (p < 0.001, global comparison). 
 
 
 JIA, Study I JIA, Study II RA PsA AxSpA 
 n = 218 n = 119 n = 1,086 n = 213 n = 277 
Age 32.7 (13.8) 32.4 (13.4) 62.6 (15.0) 53.0 (14.9) 44.9 (13.7) 
Female, % 73.4 77.3 71.2 43.7 39.4 
Disease duration in years 24.6 (14.0) 23.3 (13.3) 14.6 (10.7) 10.9 (8.9) 13.4 (11.3) 
DAS28-3 1.9 (0.8) 1.9 (0.8) 2.3 (0.8) 2.2 (0.9) 1.9 (0.8) 
HAQ disability index (0-3) 0.4 (0.6) 0.4 (0.6) 0.6 (0.6) 0.6 (0.6) 0.5 (0.5) 
Pain (VAS, 0-100) 22.2 (21.0) 22.6 (19.5) 29.4 (22.2) 29.6 (22.6) 30.6 (22.4) 
Fatigue (VAS, 0-100) 22.9 (22.9) 24.8 (24.2) 30.8 (24.3) 28.3 (23.7) 32.3 (25.3) 
Ever DMARDs, % 90.4 85.7 93.9 83.6 75.1 
Ever bDMARDs, % 43.5 40.3 23.0 33.8 41.9 
 
Table 8. Baseline characteristics (mean (SD)).
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 JIA, Study I JIA, Study II RA AxSpA PsA 
 n = 218 n = 119 n = 1,086 n = 277 n = 213 
  
Data 
Available 
(%) 
Data 
available 
(%) 
Data 
available 
(%) 
Data 
available 
(%) 
Data 
available 
(%) 
Sex 100 100 100 100 100 
Age 100 100 100 100 100 
BMI 98.2 99.2 96.5 97.5 99.1 
DAS28-3 (ESR) 87.2 94.1 93.6 78 86.9 
Pain 99.5 100 99.1 94.9 99.1 
Fatigue 99.5 100 98.9 94.2 98.6 
HAQ index  99.1 99.2 97.9 94.6 99.5 
Disease duration 53.7 60.5 93.3 59.6 77.9 
Medication data 63.3 67.2 94 75.1 83.6 
 
Table 9. Proportions of available data. Missing data for medication is mainly explained by 
patients needing no anti-rheumatic medication in adulthood. 
 
The proportion of available data in the clinical dataset are in Table 9. In the healthcare 
utilization data, diagnosis codes were available for 79.6% of healthcare contacts of 
patients with JIA, for 77.2% with PsA, for 69.8% with RA, and for 79.8% with AxSpA. 
For variables on contact type, unit, and profession of healthcare provider, data were 
available for 95.5% to 100.0%. Of the contacts lacking diagnosis code, 70.6% to 76.5% 
involved other than face-to-face contacts, the majority of which were non-physician 
contacts which have lower cost weights than do physician visits and inpatient care. 
 
5.2 Comparison of cost distributions (Study II) 
 
Although the diseases were heterogeneous with regard to patient characteristics, they 
had similar cost distributions (p = 0.88, Figure 5) with following annual health service-
related direct costs: JIA, mean 3,631€/patient/year (median 2,164€, IQR 565-4,867€); 
PsA, mean 3,816€ (median 1,477€, IQR 637-4,486€); RA, mean 4,681€ (median  
1,738€, IQR 707-4,922€); AxSpA, mean 3,571€ (median 1,382€, IQR 545-4,080€). 
Cost distributions were similar for men and women (p = 0.33).  
 
Specialty care, particularly outpatient care created the largest cost component (Figure 
6). Comprising the oldest patients, RA accounted for the highest relative inpatient 
costs (42.9%, combining primary and specialty care inpatient care). JIA and AxSpA, 
the diseases with the youngest average age, had the most outpatient-centred costs. 
Day hospital visits constituted roughly 10% of all costs, and emergency department 
visits for around 5%. 
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Figure 5. Boxplot on annual health service-related direct costs, on those with healthcare contacts 
in 2014. The cost distributions were similar (p = 0.88). Adapted from Scand J Rheumatol 2019, 
Mars et al., Patients with rheumatic diseases share similar patterns of healthcare resource 
utilization, by permission of Taylor & Francis. 
 
 
 
 
 
 
 
 
Figure 6. Proportions of costs for different healthcare units in JIA, PsA, RA, and AxSpA. 
Adapted from Scand J Rheumatol 2019, Mars et al., Patients with rheumatic diseases share 
similar patterns of healthcare resource utilization, by permission of Taylor & Francis. 
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5.3. Cost drivers 
 
5.3.1 Disease activity (Study I) 
 
A more detailed evaluation of the impact of disease activity on health service-related 
costs was performed for JIA. Out of the 137 patients with healthcare utilization data in 
2014, 11 (8.0%, mean age 32.4 years, median age 28.7) had at least one measurement of 
DAS28-3 ≥3.2 and were therefore defined as having active disease during that year. 
Those with high disease activity had higher annual costs (p < 0.01; Figure 7) than 
those with DAS28-3 <3.2 in 2014 (mean costs 6,827€/year vs 2,835€/year, median costs 
7,076€/year vs 1,311€/year). Those with active disease in 2014 showed higher levels of 
disability and pain, and higher usage of bDMARDs than did those in remission or 
with low disease activity (Table 10). 
 
 
Figure 7. Density plot for health service-related costs in Study I, comparing those with active 
disease (defined as at least one DAS28-3 measurement ≥3.2 in 2014) to those without disease 
activity (DAS28-3 < 3.2 in 2014). 
 
 
  At least once DAS28-3 ≥3.2 DAS28-3 <3.2 
Number of patients 11 (8.0%) 126 (92.0%) 
DAS28-3 3.1 ± 0.7 1.8 ± 0.7 
Pain (VAS 0-100) 30.1 ± 18.0 21.7 ± 19.4 
HAQ index (0-3) 0.9 ± 0.9 0.3 ± 0.5 
Ever bDMARDs (%) 81.8 50.0 
 
Table 10. Clinical characteristics for JIA patients with active disease in 2014 compared with 
those in remission or with low disease activity. Table modified from one published in Scand J 
Rheumatol 2018, Mars et al., Healthcare costs and outcomes in adult patients with juvenile 
idiopathic arthritis: a population-based study, by permission of Taylor & Francis. 
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5.3.2 Patient-reported outcomes (Study II) 
 
To assess patterns underlying high healthcare utilization, we first defined high 
healthcare utilization by selecting a quantile cutpoint at which those above it 
accounted for a cost identical to the of those below it. In adult patients with JIA, 15% 
utilized as much as did the other 85%, with this ratio being 10%/90% in patients with 
PsA, RA, or AxSpA. High utilizers showed slightly higher levels of disease activity, 
although disease activity was generally low. Moreover, high healthcare utilizaters 
showed worse levels in many of the patient-reported outcomes: those with high 
utilization presented with higher average HAQ, pain, and fatigue than did the rest (p 
< 0.05 for all except pain for AxSpA and fatigue for PsA; Figure 8). However, in RA 
and AxSpA, high utilizers were also somewhat older (p <0.001 and p<0.05). 
 
 
5.3.3 Comorbidity (Study II) 
 
Comordidities incurred the largest proportion of the health service-related direct 
costs: in JIA, RA, PsA, and AxSpA, the index rheumatic disease comprised only 
43.6%, 32.5%, 33.2%, and 31.9% (Figure 9). Compared to low utilizers, the proportional 
costs of comorbidities were much higher in high utilizers: in JIA, comorbidities 
accounted for 49.4% of the costs of low utilizers and for 63.1% of high utilizers. In PsA, 
these proportions were 56.8% and 76.9%, in RA 56.0% and 78.2%, and in AxSpA 57.6% 
and 78.5%. One-fourth of the patients had at least one healthcare contact because of 
infections in 2014, but their costs incurred only 1.9%–6.2%. CVDs were most common 
in RA, with 27.9% having at least one healthcare contact for CVDs. These CVD 
contacts incurred 12.8% of the annual costs in RA patients. Of patients with JIA, 13.4% 
had contacts for eye disorders (3.1% of costs) and in patients with AxSpA, 15.2% (2.5% 
of costs). 
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Figure 8. For high- and low-utilization groups, distributions of individual medians of clinical 
variables. Adapted from Scand J Rheumatol 2019, Mars et al., Patients with rheumatic diseases 
share similar patterns of healthcare resource utilization, by permission of Taylor & Francis.
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Figure 9. The proportions of annual costs incurred by rheumatic diseases and comorbidities. 
 
 
5.4. Patterns of utilization in RA (Study III) 
 
To explore whether the cost drivers incurred followed certain patterns, we used 
cluster analysis to study RA. The clustering variables were health service-related costs, 
median DAS28-3, median HAQ index, and median pain. The dendrogram illustrating 
cluster arrangement is in Figure 10, baseline characteristics for each cluster in Table 
11, and distributions for the clustering variables within each cluster are in Figure 11. 
 
We established four clusters, each expressing a recognizable pattern. C1 (“Remission 
and low costs”, 550 patients, 58.6%) was the largest cluster comprising the youngest 
patients (mean age 58.7). Their mean costs and disease activity were low and they 
showed minimal disability. Their average number of comorbidities was the lowest, 2.1.  
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All groups showed rather high levels of pain, with the highest group mean at 53.3 in 
C2 (“Chronic pain, disability and fatigue”, 269 patients, 28.6%). The mean being 
counted from individual medians indicates that many of these patients have 
experienced chronic pain. Other characterizing features in C2 were high average levels 
of disability, and fatigue. In C2, 13.4% had physician-diagnosed fibromyalgia, but in 
the other clusters, this was reported only in 3.6% in C1, 7.2% in C3, and 4.3% in C4. 
 
C3 (“Inflammation,” 97 patients, 10.3%) had rather high mean costs along with high 
disease activity. Almost half the patients were current or previous users of 
bDMARDs. Despite having higher disease activity than C2 (“Chronic pain, disability 
and fatigue”), patients in C3 (“Inflammation”) had lower average levels of pain and 
somewhat less disability. As regards disease activity, however, all clusters were rather 
heterogeneous. 
 
 
 
Figure 10. Cluster dendrogram - a tree graph illustrating cluster arrangement in hierarchical 
clustering. 
 
 
 
 C1 C2 C3 C4 
  n = 550 n = 269 n = 97 n = 23 
Age, mean (SD) 58.7 (14.9) 66.6 (12.9) 66.8 (13.7) 69.2 (13.5) 
Women, % 70.4 72.9 69.1 73.9 
Disease duration, mean (SD) 12.2 (8.6) 16.7 (12.5) 15.8 (11.9) 15.8 (11.3) 
Fatigue, mean (SD) 20.0 (18.7) 50.6 (20.6) 32.1 (19.2) 33.1 (23.7) 
Ever bDMARDs. % 22.7 24.5 46.4 39.1 
Number of comorbitities, mean 2.1 3.7 3.5 5.2 
Mean total costs/patient, € 2,600 4,568 6,807 45,251 
 
Table 11. Baseline characteristics of the four clusters.
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C4 (“Comorbidities and high costs”) was small and heterogeneous, and all 23 patients 
(2.4%) had unusually high costs incurred by costly comorbidities, which encompassed 
mainly gastrointestinal conditions such as malignancies or bleeding, other 
malignancies, severe infections, and postoperative complications. 
 
The clusters had similar proportions of erosions in hands or feet (p = 0.24), and similar 
seropositivity (p = 0.57). Results remained similar when repeating the analysis without 
costs, but incorporating costs increased the discriminative capacity (results not 
shown). Proportion of costs by healthcare unit are in Figure 12. In the PCA, cluster 
overlap was evident, and C3 showed the most overlap with the other clusters, and C4 
was heterogeneous (Figure 13). 
 
 
 
 
Figure 11. Boxplots of the clustering variables with group means above each plot. C1 = 
“Remission and low costs”, C2 = “Chronic pain, disability, and fatigue”, C3 = “Inflammation”, 
C4 = “Comorbidities and high costs”.
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Figure 12. Proportions of costs by healthcare unit. 
 
    
Figure 13. Plotting the second principal component (PC2) against the first principal component (PC1) indicates cluster overlap. C1 to C4 from the hierarchical 
cluster analysis are highlighted. These first two principal components explained 73.1% of the total variance. 
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5.5. Long-term outcomes in JIA (Study I) 
 
5.5.1 Disease activity, pain, and disability 
 
We compared adult patients under age 30 (n = 119) with those 30 and older (n = 99), 
as these individuals have fallen ill in eras of different treatment regimens. 90.4% were 
current or past users of any DMARDs, and 43.5% had received bDMARDs. Out of 
individuals under 30, 85.6% had a median DAS28-3 less than 2.6, while in those over 
30, the proportion was 72.9% (Figure 14). Figure 15 shows density plots for HAQ, pain, 
and fatigue in comparisons of those under and over age 30. Individuals over 30 showed 
higher levels of these patient-reported outcomes (p < 0.001 for all). In those under age 
30, 85.7% had the a rather good functional capacity (individual median HAQ less than 
0.5), but this proportion was only 45.4% for those over 30. Results remained 
unchanged when those over age 60 were excluded (results not shown). 
 
5.5.2 Work outcomes 
 
Employment status on their most recent visit to the rheumatology clinic differed 
between the two age groups (p < 0.001). In those 30 years or older, 26 patients (26.3%) 
were retired or reported that they were entitled to part-time or full-time disability 
pensions. Of these 26, 20 were younger than 63 years, which is currently the youngest 
regular retirement age in Finland. Therefore, at least 20 patients (20.2%) among those 
over age 30 received disability pensions, compared to 0.8% in those under age 30. In 
those 30 or older, 6.1% were on sick leave on their most recent visit, whereas this 
proportion was only 0.8% for those under 30. 
 
 
Figure 14. Adult JIA patients by different disease activity categories, <2.6 indicating minimal 
disase activity or remission, 2.6-3.2 low disease activity, and ≥3.2 active disease (Study I). 
Adapted from Scand J Rheumatol 2018, Mars et al., Healthcare costs and outcomes in adult 
patients with juvenile idiopathic arthritis: a population-based study, by permission of Taylor & 
Francis. 
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Figure 15. Distributions for HAQ, pain, and fatigue for adult patients with JIA under and over 
age 30. 
 
 
5.5.3 Cost outcomes 
 
In total, the annual health service-related direct costs for the 137 patients in the 
healthcare utilization data were 432,257€ in 2014 (mean costs=3,155€ per patient/year, 
median=1,569€ per patient/year). In patients under age 30 (n = 80), the annual health 
service-related costs were lower than those for patients older than 30 (n = 57; mean 
costs = 2,386€ vs 4,235€ per patient/year, median = 844€ vs 2,772€ per patient/year) 
(p < 0.001, density plot in Figure 16). 
 
The only factor associated with costs in both the univariate and multivariate analyses 
was raw HAQ (beta = 0.081, p = 0.03 in the multivariate analysis, marginal effect 
228€, 95% CI 3-453€; Figure 17). In separate analyses for individuals under and over 
30, this association was detected only for individuals over 30 (beta = 0.066, p = 0.02 
in the multivariate analysis, marginal effect 228€, 95% CI 10-446€; Figure 17). 
 
Of these 137 patients, 36 (26.3%) used bDMARDs in 2014 for a total of 355 months 
(mean 9.9 months/patient), the total annual cost of bDMARDs amounting to 
355,000€ (9,861€ per patient/year). 
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Figure 16. Density plot for health service-related costs for the adult JIA patients under and over 30 years of age. 
 
 
Figure 17. Factors affecting annual health service-related direct costs in adult patients with JIA. 
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6. DISCUSSION 
 
6.1 Main findings 
 
JIA, RA, PsA, and AxSpA shared similar patterns of healthcare resource utilization, 
both in terms of costs incurred by the rheumatic disease and by comorbidities. In these 
diseases, a minority can be recognized as high healthcare utilizers. These high utilizers 
presented with worse levels for patient-reported outcome measures, and they had a 
costlier comorbidity burden. Throughout Studies I to III, in addition to disease 
activity, patient-reported outcomes, particularly pain, but also fatigue and disability 
emerged as key factors affecting healthcare resource utilization. Furthermore, we 
provide evidence as to improved outcomes in the biologic era for adult patients with 
JIA. 
 
This observational, population-based study illustrated how research on rheumatic 
diseases can benefit from well-recorded data on healthcare resource utilization by 
integrating it into clinical data on patient-reported outcome measures in a country 
with large-scale public healthcare. This was also leveraged with a data-driven 
approach in Study III, where we identified RA patient groups in need of targeted 
measures. The cost drivers identified in Studies I and II were evident in these clusters, 
merging into fairly distinct patterns. Importantly, unmet needs in terms of pain, 
disability, and fatigue were identified in a cluster comprising one-third of patients. 
 
6.2 Similar cost distributions 
 
Overall, patients with JIA, PsA, RA, and AxSpA had similar patterns of healthcare 
resource utilization. At a young age, adult patients with JIA and AxSpA displayed 
utilization patterns similar to those of much older patients with RA. This finding is 
important, because with disease onset occurring at earlier stages of life, JIA and 
AxSpA will likely lead to higher cumulative life-time costs. 
 
Considering the heterogeneity of patients, methodology, and healthcare systems, our 
cost estimates of health service-related direct costs are similar to those reported by 
prior studies.129,324,326,339  This heterogeneity also makes more detailed comparisons with 
prior studies challenging. Although some previous comparison studies have explored 
both the economic and disease burden, those studies took place in a different era of 
treatments, and none include JIA.96,324,340,341 In these earlier comparison studies, the 
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overall disease burden is reported to be similar in RA, PsA, and AxSpA or AS.3,96 In 
terms of costs, a review by Franke and colleagues comparing costs of RA (at mean age 
57) and younger patients with AS (at mean age 47) found that RA incurred higher 
direct, rheumatic disease-related costs.339 Another study by Verstappen and colleagues 
reached similar conclusions.341 However, Franke and colleagues found that the relative 
cost distribution across different cost domains was approximately similar,339 which 
was also our conclusion. Although no difference between the costs was statistically 
apparent, the median costs were highest in JIA, and the mean costs were highest in 
RA, mainly due to outliers in RA with very high costs. 
 
That we found the diseases to have rather similar cost distributions may also result 
from the fact that we did not aim to compare medication costs. Given the somewhat 
different treatment strategies and age of onset, we would expect there to be differences 
for cost components such as medication costs, and work disability and the resulting 
indirect costs. 
 
6.3 A minority of patients incur the majority of costs 
 
In JIA, 15% incurred as much cost as the remaining 85%. For PsA, RA, and AxSpA, 
this proportion of high utilizers was 10%. A Swedish study on annual total costs of RA 
patients that included also costs of medication and work loss, reported this proportion 
to be very similar to ours, 13%.291 Moreover, a study from the pre-biological era by 
Minden and colleagues found that in young adults with JIA, 12% were responsible for 
55% of the total healthcare costs.318 Similar estimates exist also for direct costs in AS.129 
Although varying definitions of cost elements, as well as different study populations 
and healthcare systems limit detailed comparison, these findings suggest that the 
pattern of high utilization is rather consistent across rheumatic diseases. Studies of the 
general population and of other chronic diseases imply that 5% to 10% are high 
utilizers.342-345 
 
We were unable to assess the consistency of high utilization over a longer time period. 
A comprehensive Canadian study within the general population reported that the 
high-utilization category represented moderate stability over a three-year period. 
Approximately 45% of people above the 95th percentile stayed above the 90th percentile 
during the consecutive two years. Mortality was, however, high above the 95th 
percentile. Similarly, approximately 51% of those in the 90th to 94th percentile category 
remained at or above this level in both of the subsequent years.346 
 
Between high utilizers and the rest of the patients, two differences emerged. Firstly, 
in high utilizers, the proportional costs of comorbidities were higher than in the rest 
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of the patients. Secondly, high utilizers showed slightly worse levels of disease activity 
and worse patient-reported outcomes. 
 
6.4 Disease activity and costs 
 
Despite exposing some link between disease activity and costs, many of our findings 
also allow us to draw some encouraging conclusions. Overall, the individual median 
levels of disease activity were low both in high utilizers and in the rest of the patients. 
In JIA, most patients had no disease activity or at most low disease activity in 
adulthood. In the cluster analysis of RA, two clusters, C1 and C3, implied that 
aggressive treatment strategies in RA have resulted in positive outcomes for the 
majority. C1 (“Remission and low costs”, 58.6% of patients) was the largest cluster with 
favorable outcomes, including low disease activity, and low health service-related 
direct costs. C3 (“Inflammation”, 10.3% of patients), although heterogeneous, had the 
highest individual medians of DAS28-3, but their other outcomes such as pain and 
disability levels were rather favourable, suggesting that although many have showed 
acute or chronic inflammation, effective treatment strategies have helped to maintain 
many patients’ physical functioning. These findings are in line with ones discovered 
earlier of a generally improved outlook for many patients with rheumatic diseases in 
the era of modern treatment strategies.15,347,348 
 
We performed a more detailed analysis of the impact of disease activity on costs for 
JIA patients in Study I. Patients with active disease, defined as at least one DAS28-3 
measurement ≥3.2 in 2014, had annual health service-related direct costs over twice as 
high as those of patients with no or low disease activity. In children with JIA, costs are 
generally skewed toward patients with active disease.315 With a median age of 28.7, our 
JIA patients with active disease were rather young. To better understand this pattern 
of high disease activity in conjunction with high health service-related costs in JIA, 
larger studies are warranted. Assessing the impact of important treatment challenges, 
such as poor adherence to treatment349 can be recommended for future studies. 
 
6.5 Impact of patient-reported outcome measures on costs 
 
In all the studies, patient-reported outcomes, particularly pain but also disability, were 
important factors affecting healthcare resource utilization. As mentioned earlier, high 
utilizers with JIA, RA, PsA, or AxSpA showed worse levels of patient-reported 
outcomes, with the largest differences emerged for pain, but also for disability and 
fatigue. Although being conducted over a decade ago, a Swedish study by Hallert and 
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colleagues reached similar conclusions, with high utilizers with RA having higher 
HAQ and higher levels of pain.350 
 
In Study III, characterizing features of cluster C2, which comprised one-third of the 
RA patients, were chronic pain, disability, and fatigue. However, only half of them 
showed moderate or higher disease activity, and fibromyalgia was diagnosed in 13.4%, 
indicating that much of their symptoms were not explicitly linked to disease activity; 
instead, many of these patients seemed to have chronic, multifactorial pain. 
 
Pain, fatigue, and an impairment in quality of life are often reported residual symptoms 
in RA.351 Fatigue is associated with various features of rheumatic diseases: disease 
activity, disability, and the comorbidity burden.51 Fatigue is also often linked to chronic 
pain. When Lee and colleagues explored subgroups of RA patients to examine pain, 
fatigue, inflammation, and psychosocial factors, they reached similar conclusions with 
subgroups similar to our clusters C1, C2, and C3. Patients who showed high levels of 
pain presented with minimal inflammation but with symptoms indicative of chronic 
widespread pain syndrome.352 
 
In rheumatic diseases, both pain and fatigue in are multifactorial.148,353 Pain can result 
from active inflammation which may lead to irreversible joint destruction, but pain-
regulation mechanisms may also be altered.148 In the general population, pain is 
likewise an important factor affecting healthcare expenditures.354,355 Depression in RA 
patients is associated with increased levels of patient-perceived global disease activity 
and pain.356 Depression is also a common comorbidity in other patients with pain357 
and some have found it to be highly prevalent in high healthcare utilizers.358  
 
Recent reviews and guidelines identify pain and physical functioning as important 
areas of unmet needs in RA.359,360 Regardless of its aetiology, pain both acute and 
chronic should receive active treatment in rheumatic diseases, both by both lowering 
disease activity, and by treating the pain itself by with both pharmacological and non-
pharmacological treatment, such as exercise therapy or sometimes by means of 
orthopaedic surgery. Patients with chronic pain might also benefit from the support 
of a multiprofessional team. 
 
A link between disability and costs was apparent in all of our studies, a finding 
supported by numerous earlier investigations.129,305,322-324,327 Despite our small sample 
size for JIA, disability measured by HAQ was associated with costs. HAQ is affected 
by multiple factors such as age and other sociodemografic factors. 196,217 Our HAQ 
variable comprised individual medians, reflecting the average level of disability over 
the whole follow-up. In early RA, HAQ increases, and it tends to decrease when the 
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initial acute inflammation is treated, increasing again if chronic impairment and joint 
damage occur.361 
 
6.6 Comorbidities – a substantial cost component 
 
We can draw two important conclusions from our results on comorbidity. Firstly, the 
health service-related costs of comorbidites between the rheumatic diseases were fairly 
similar. Although overlooked by many studies, the finding that a majority of costs in 
rheumatic diseases may be incurred by comorbidities is supported by earlier 
research.303 Overall, for RA, PsA, and AxSpA, only about one-third of costs (for JIA, 
43.6%) were incurred by rheumatic diseases; comorbidities caused two thirds of the 
costs. To our knowledge, this is the first study in adult JIA patients to describe the 
comorbidity burden as to both the detailed comorbidity prevalence and the resulting 
direct healthcare resource utilization, and to assess them alongside figures for other 
rheumatic diseases. Furthermore, for RA, PsA, and AxSpA, few have assessed 
comorbidity-related costs this widely, and few studies have included comorbidities 
that are not directly linked to the index rheumatic disease.97,303,362 
 
Our second, albeit a more careful conclusion is that higher rheumatic disease activity 
may have contributed to a greater and costlier comorbidity burden. Looking at high 
utilizers only, the proportion of comorbidity costs was higher than when looking at all 
patients; the proportion of rheumatic disease costs was only one-fourth (a third for 
JIA) of the total costs for RA, PsA, or AxSpA. Given that high utilizers comprised a 
higher proportion of bDMARD ever-users and had slightly higher levels of DAS28-3, 
they may have had a history of more inflammation. Due to the small absolute number 
of high utilizers, we were unable to assess this finding further. 
 
In Study III, the most distinct feature of the smallest cluster, C4, was that these 
patients had severe and costly comorbidities, in particular, consisting of severe 
infections, cancer, and severe gastrointestinal disorders, all of which may potentially 
be linked RA. These patients also had a rather high average level of DAS28-3, and 40% 
were previous or current users of bDMARDs. 
 
An association between disease activity and cardiovascular diseases is well 
recognized.49,363 Crepaldi and colleagues examined the relationship between RA 
disease activity and comorbidities, concluding that among the many comorbidities 
assessed, disease activity was influenced by cardiometabolic comorbidities, in 
particular diabetes, ischaemic heart disease, and obesity.364 
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6.7 Identifying patterns of utilization in RA 
 
Although over half the patients did generally well with their disease and had low costs, 
we also identified patients with unmet needs in terms of pain, fatigue, disability, and 
comorbidities. Our analysis demonstrated a data-driven approach to identify patients 
with RA in need of targeted measures. Cluster analysis captures information beyond 
that identified by traditional research methods, and has verified clinically relevant 
clusters in many medical specialties365,366; studies in clinical rheumatology have applied 
cluster analysis for ANCA-associated vasculitis 367 and gout.368 Some studies have 
undertaken efforts to subgroup arthritis patients based on patient-reported 
outcomes,352,369 but to our knowledge, no studies have included costs when clustering 
RA patients. 
 
Despite identifying rather distinct clusters, these were still fairly heterogeneous. 
Finding more homogeneous clusters would require selecting a much smaller number 
of clusters. Cluster analysis is also sensitive to the selected clustering variables, and 
differing sets of variables highlight different aspects, likely bringing out somewhat 
different subgroups. Studying the indirect costs within these clusters would provide 
additional insights and we speculate that indirect costs would be high particularly for 
cluster C2 (“Chronic pain, disability, and fatigue”). 
 
6.8 Long-term outcomes in JIA 
 
The aim of treatment of JIA in both children and adults is no disease activity and full 
functional capacity. Timely introduction of MTX and bDMARDs has led to great 
progress JIA treatment.370 Still, many patients fail to achieve remission, either in 
childhood or later in adulthood. Studies estimate that approximately half continue to 
show disease activity in long-term follow-up, but many of these patients had fallen ill 
in a different era of treatments.69-71  
 
Differences in healthcare systems, and heterogeneous study populations and cohorts, 
particularly regarding disease subtypes, limit comparability of our findings with those 
of earlier studies.69,72,318,371,372 Our estimate of patients with active disease was much 
lower than were previous estimates,70-72 at only 8%, and most patients with JIA had low 
or no disease activity in adulthood. This lower estimate may be affected especially by 
two factors. Firstly and importantly, our data represent a modern population-based 
JIA cohort in which many patients had received modern treatment regimens, which is 
likely to have influenced their outcomes. Secondly, our estimate is, however, also likely 
to be an underestimation of disease activity, because our definition of disease activity 
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was limited to one year and we were unable to reliably identify individuals with active 
extra-articular manifestations such as active uveitis. Despite ours being a population-
based dataset, some patients with favourable outcomes in early childhood may not 
have been included. 
 
Our aim was to assess the long-term outcomes of JIA in adulthood, and the impact 
effective treatment strategies have had on this patient group, by comparison of 
patients under and over age 30, that is, before and after advances occurred in treatment 
strategies. Patients younger than 30 showed lower costs, lower levels of disease 
activity, and considerably more favourable patient-reported outcomes than did 
patients older than 30. In those under 30, disability was rare, but in those over 30, 
disability pension was common and present for one-fourth, despite their rather low 
mean age of 44.6. In these older patients, the individual median HAQ level exceeded 
0.5 in 54.6% and on these patients’ most recent visit to the rheumatology clinic, HAQ 
was 0 in only 40.4%. A long history of JIA before modern treatment strategies and 
availability of bDMARDs may have permanently damaged their joints, manifesting as 
worse physical functioning leading to higher healthcare resource utilization. 
Fortunately, modern treatment regimens make it unlikely that the younger patient 
group will have to face the outcomes of the older group. Although our findings suggest 
a decreased disease burden resulting from modern active treatment strategies, the aim 
of no disease activity and full functional capacity is still to be met. 
 
6.9 Strengths 
 
This study linked two population-based datasets: a clinical dataset with longitudinal 
follow-up and high diagnostic validity, and healthcare utilization data covering all 
public healthcare visits in a country with universal public healthcare. 
 
Studies are frequently unclear as to whether they have looked at only index disease-
related costs at all-cause costs. Healthcare resource utilization is often evaluated with 
questionnaires, some of which have extrapolated 3-month utilization to a 
year.295,327,341,350,373 One study on AS reported that patients appear to overestimate their 
healthcare visits in comparison to routine general-practice and hospital administrative 
records.327 Our utilization data represent true utilization recorded by healthcare 
professionals both in primary and specialty care, and it includes not only healthcare 
contacts for rheumatic diseases, but also for other diseases. The specialty care costs 
represent the true societal payments. Patients in long-term remission are in Finland 
followed up annually in primary care, and even if the only contact were laboratory 
monitoring for DMARDs, that patient would still be included in the utilization data. 
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The patients were diagnosed, treated, and followed up in a rheumatology clinic. 
Changes in rheumatologic diagnoses are registered, which reduces the risk for 
misclassification. Comorbidities in the clinical data are verified by rheumatologists 
and the clinical measures are widely used in clinical practice. Both datasets were 
collected as part of routine practice by healthcare professionals, and the extent of 
missingness in key variables was low. 
 
6.10 Limitations 
 
This study has some important limitations. Heterogeneity of populations and 
healthcare systems limit comparability to prior studies. The impact of potential coding 
errors and misclassification in the healthcare utilization data, a limitation shared with 
other administrative data,274 is reduced by use of larger disease categories instead of 
detailed diagnosis codes. The private sector in the region studied treats mainly private 
insurance-holders and occupational-care patients, and so the costs are minor 
compared to those in public healthcare. We expect this mainly to lead to 
underestimation of our comorbidity costs. 
 
Our aim was to assess only health service-related direct costs. We did not aim to 
compare indirect costs nor costs of medications and did not retrieve that sort of data. 
Costs of bDMARDs administered in the day hospital were under the day-hospital 
costs, and bDMARDs are likely to constitute the largest cost component.374 Indirect 
costs and costs of medications are important components of the economic burden, and 
it is likely that differences between rheumatic diseases would arise if these were 
compared. However, the largest differences in medication costs would arise primarily 
from differences in bDMARD use. 
 
The number of JIA patients with active disease was too low for more detailed analyses 
and we decided to leave out detailed cross-sectional individual data, such as current 
medications of those with active disease, and focus on group-level differences. 
Investigating indirect costs in JIA would require a larger number of patients, perhaps 
as a collaboration with multiple clinics or with addition of nationwide data. A larger 
study would also allow assessment of patterns for work disability in the younger 
patients, since disability pensions and sick leaves in our JIA patients under age 30 were 
almost non-existent. Moreover, the spectrum of reasons for disability pensions is 
expected to be large. 
 
Although many clinical trials have used DAS28 to evaluate disease activity in PsA, it 
is formally validated only for RA.159 It is not validated for adult patients with JIA, nor 
is it the primary choice for AxSpA. For these diseases, DAS28 may underestimate 
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disease activity, mainly due to not capturing the spectrum of symptoms involved in the 
disease.168,375 However, DAS28 is widely applied to measure disease activity index in 
adult rheumatology clinics, where adult JIA patients receive treatment. Based on our 
clinical experience, patients who are intensively followed up in our rheumatology clinic 
in adulthood have symptoms of juvenile polyarthritis or extended oligoarthritis, 
supporting the applicability of DAS28. A study by Miyamae and colleagues also 
applied DAS28 when investigating long-term outcomes of JIA in adult Japanese 
patients, 93% of whom had poly- or oligoarthritis.372 
 
JIA subtypes were instinguishable in our data. Bertilsson and colleagues found that 
after 17 years of follow-up, the subtype at onset had changed in up to 44%.66 Therefore, 
after a patient’s transition to adult rheumatology clinics, the disease subtype may not 
always be distinguishable, particularly a few decades after disease onset, which was 
the case in our registry-based study. Many were diagnosed in the Rheumatism 
Foundation Hospital (1951-2010), which no longer exists, hindering access to 
information recorded at disease onset.  
 
Because disease activity is an important cost driver in other inflammatory rheumatic 
diseases, this was an important area to study in JIA. Using this narrower definition of 
disease activity allowed us to explore the economic burden of this rare disease in the 
modern era of treatment. In the multivariate regression analyses, disease activity was 
not associated with annual health service-related direct costs, but our study may also 
be underpowered to detect such associations. 
 
6.11 Impact and generalizability 
 
Firstly, the major findings of our study relate to the impact of patient-reported 
outcomes, particularly pain, on healthcare resource utilization. Secondly, we 
expanded previous observations that comorbidity is an important cost driver in 
rheumatic diseases. Thirdly, this study also achieved one of its main objectives, which 
was to report and explore patterns of healthcare utilization of patients of a Finnish 
rheumatology clinic with highly elaborate care chains. We also illustrated how 
research on rheumatic diseases can benefit from well-recorded data on healthcare 
resource utilization by integrating it into clinical data on patient-reported outcome 
measures in a country with large-scale public healthcare. 
 
Being conducted in a population-based setting, this study provided results that are 
representative of the Finnish population and can be generalized to similar healthcare- 
and social-security systems, particularly in Nordic countries. Finland has large-scale 
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public healthcare, which is mainly tax-funded. Applying these results to insurance-
based healthcare systems would require more confidence in labelling and careful 
consideration of the ethical aspects, since clustering could essentially be used to 
pigeonhole patients into various health plan categories. However, the healthcare 
needs that this thesis highlights are likely to be relevant also outside the Nordic 
coutries. 
 
6.12 Future research 
 
Along with complementary data on indirect costs and costs of medications, the 
findings of this study need to be repeated in larger datasets with longer follow-up. The 
ever-growing databases can be useful in further assessing these associations by 
combinining clinical and administrative datasets with large-scale biological 
information, such as genomic data. Particularly for JIA, leveraging information on 
disease subtypes is important in the future. Further comparison studies are needed 
involving a wider spectrum of diseases such as systemic lupus erythematosus. 
 
The indirect costs are of particular interest in individuals with poor patient-reported 
outcomes, who comprised one-third of the RA patients. Moreover, the cluster analysis 
could be performed for all rheumatic diseases simultaneously, or for individual 
rheumatic diseases beyond RA, if data is available for a sufficient number of patients. 
As research applying cluster analysis is, above all, hypothesis-generating, this might 
reveal further interesting patterns for advanced analyses performed in more traditional 
research frameworks.  Analyses in the large databases may also highlight more detailed 
disease patterns accountable for both favourable and unfavourable outcomes. 
 76 
7. CONCLUSIONS 
 
I: Modern treatment regimens have entailed good long-term outcomes for the 
majority of JIA patients, although room still exists for improvement in terms of 
reducing disease activity and disability. 
II: Patients with JIA, RA, PsA, and AxSpA shared similar patterns of healthcare 
resource utilization, both in terms of costs incurred by the rheumatic disease and by 
comorbidities. Of the health service-related direct costs, two-thirds were comorbidity 
costs. Approximately one-tenth of these individuals can be classified as high healthcare 
utilizers. Patient-reported outcomes, particularly pain, were important cost drivers. 
III: A large proportion of RA patients are doing well and have low healthcare resource 
utilization. Unmet needs identified in one-third of patients were pain, disability, and 
fatigue.  
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